Construction and characterisation of a stably transfected BHK cell line permanently secreting the canine interleukin 12  as a source for adoptive cancer immunotherapy in dogs by Kocoski, Vladimir
  
                                                                                                                                             
 
 
 
 
CONSTRUCTION AND CHARACHTERISATION OF A STABLY 
TRANSFECTED BHK CELL LINE PERMANENTLY SECRETING THE 
CANINE INTERLEUKIN 12 AS A SOURCE FOR ADOPTIVE CANCER 
IMMUNOTHERAPY IN DOGS 
 
 
 
 
 
 
 
 
Inaugural Dissertation 
submitted to the 
Faculty of Veterinary Medicine 
in partial fulfillment of the requirements 
for the PhD-Degree 
of the Faculties of Veterinary Medicine and Medicine 
of the Justus Liebig University Giessen 
 
 
 
 
 
 
 
 
 
by 
Kocoski, Vladimir 
 
of 
Struga, 
Republic of Macedonia 
 
 
 
Giessen 2008 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                                                             
 
 
 
 
 
 
 
 
From the Institute of Veterinary Pathology 
Director: Prof. Dr. Manfred Reinacher 
of the Faculty of Veterinary Medicine of the Justus Liebig University Giessen 
 
 
 
 
 
 
 
 
 
 
 
First Supervisor and Committee Member:  
Prof. Dr. Eberhard Burkhardt 
 
Second Supervisor and Committee Member:  
Prof. Dr. Lothar Stitz 
 
Committee Members:  
           Prof. Dr. Dr. Hans Michael Piper 
 Prof. Dr. Holger Hackstein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date of Doctoral Defence: 
31.03.2008 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I declare that I have completed this dissertation single-handedly without the 
unauthorized help of a second party and only with the assistance 
acknowledged therein. I have appropriately acknowledged and referenced all 
text passages that are derived literally from or are based on the content of 
published or unpublished work of others, and all information that relates to 
verbal communications. I have abided by the principles of good scientific 
conduct laid down in the charter of the Justus Liebig University of Giessen 
in carrying out the investigations described in the dissertation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
TO MY PARENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Content                                                                                                                                             
 
1 INTRODUCTION               1 
2 LITERATURE OVERVIEW             3 
2.1 DNA Cloning                3 
2.2 Protein expression in mammalian cells            4 
2.2.1 General principles               4 
2.2.2 The Tet System for inducible mammalian expression          5 
2.3 Biology of IL-12 in human and mice            6 
2.4 Biology of IL-12 in the dog            10 
2.5 IL-12 as a single chain            10 
2.6 Investigation of the IL-12 effects on PBMC          11 
2.6.1 PBMC Isolation             11 
2.6.2 Cytotoxicity assay             12 
2.6.3 Cell proliferation             13 
3 MATERIALS AND METHODS           14 
3.1 Cloning              14 
3.1.1 Polymerase Chain Reaction            14 
3.1.1.1 KOD Hot Start DNA Polymerase           14 
3.1.1.2 Taq Polymerase             15 
3.1.1.3 A-overhang addition and TA cloning          15 
3.1.2 Gel electrophoresis             16 
3.1.3 Restriction digestion             16 
3.1.4 Ligation              17 
3.1.5 Transformation of E.coli            17 
3.1.6 Plasmid DNA extraction            18 
3.2 Construction of the recombinant canine single chain IL-12 (rcscIL-12)      19 
3.2.1 Completion of the cDNA coding for the IL-12 p35 sequence       19 
3.2.2 Correction of the IL-12 p40 cDNA sequence  
(DpnI site-directed mutagenesis)           20 
3.2.3 Construction of the rcscIL-12           21 
3.2.4 Construction of the rcscIL-12/IREs/Luciferase/pTRUE plasmid       22 
3.3 Establishing of a stably transfected BHK Tet-On cell line        22 
3.3.1 Stable transfection             22 
 
                                                                                                                                           Content 
 
3.3.2 Cloning of the transfected cells           23 
3.3.3 Luciferase assay             24 
3.3.4 Immunofluorescence             24 
3.3.5 SDS-PAGE              25 
3.3.6 Western blot              26 
3.4 Detection of the rcscIL-12 bioactivity          27 
3.4.1 PBMC isolation             27 
3.4.2 PBMC pre-stimulation            27 
3.4.3 IFN-γ ELISA              28 
3.4.4 BrdU ELISA              29 
3.4.5 Cytotoxicity assay (Rose Bengal Assay)          30 
4 RESULTS              32 
4.1 Construction of the rcscIL-12           32 
4.1.1 Repair of the cDNA coding for the IL-12 p35 sequence        32 
4.1.2 Correction of the cDNA coding for the IL-12 p40 sequence       33 
4.1.3 Construction of the rcscIL-12           34 
4.1.4 Construction of the rcscIL-12/IRES/Luciferase/pTRUE plasmid       34 
4.2 Establishing of rcscIL-12 containing BHK Tet-On cell line       36 
4.2.1 Transfection of the BHK Tet-On cell line          36 
4.2.2 Detection of the rcscIL-12 in the established cell line        41 
4.2.2.1 Detection of the rcscIL-12 protein           41 
4.2.3 Confirmation of bioactivity of the IL-12-          42 
4.3 Investigation of the biological effects of rcscIL-12 on canine PBMC      45 
4.3.1 Resting canine PBMC do not produce IFN-γ after stimulation with IL-12      45 
4.3.2 IL-12 requires presence of IL-2 to induce IFN-γ production  
in IL-2 lymphoblasts             46 
4.3.3 Proliferation of canine IL-2 lymphoblasts upon IL-12 stimulation       47 
4.3.4 Evaluation of the cytotoxic activity of canine IL-2 lymphoblasts  
upon stimulation with IL-12            48 
5 DISCUSSION             50 
6 SUMMARY              55 
7 ZUSAMMENFASSUNG            57 
 
  
Content                                                                                                                                             
 
8 BIBLIOGRAPHY             59 
9 ATTACHMENT        I-VII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Abbreviations                                                                                                                                             
 
Abbreviations 
 
A  Adenine  
AAV  Adeno-associated viruses 
AP  Alkaline phosphatase  
APC  Antigen presenting cells 
APS  Ammonium persulfate 
BCIP  (5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt)  
BHK  Baby hamster kidney 
Blasts  Cells stimulated to divide 
bp  Basepair 
BrdU  5-bromo-2-deoxyuridine 
CD  Cluster of differentiation 
cDNA  Complementary deoxyribonucleic acid 
CMV  Cytomegalovirus 
CRA  Chromium release assay 
CTAC  Canine thyreo adenocarcinoma  
C  Cytosine  
Cy-5  Carbocyanine 5 
DC  Dendritic cells 
ddH2O  Double-destillated water 
DNA  Deoxyribonucleic acid 
dNTPs  Deoxynucleo triphosphates 
EDTA  Ethylenediamine tetraacetic acid 
FL  Fas ligand 
G  Guanine  
H2O2  Hydrogen peroxide  
H2SO4  Sulfuric acid 
IFN-γ  Interferon gamma 
cIFN-γ  Canine Interferon gamma 
IL-2  Interleukin 2 
IL-12  Interleukin 12 
IL-12R Interleukin 12 receptor 
                                                                                                                                 Abbreviations 
 
IRES  Internal ribosomal entry site 
kb  Kilobasis 
KOD  Kodakaraensis, Thermococcus  
LAK cell Lymphokine activated killer cell 
LPS  Lipopolysacharide 
mA  Miliampers 
µg  Microgram  
MgCl2  Magnesium chloride 
MgSO4 Magnesium sulfate  
min.  Minutes 
µl  Microliter 
ml  Mililiter 
mM  Milimole 
MTT  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
mRNA Messenger ribonucleic acid 
NaCl  Sodium (Natrium) cloride 
NBT  (Nitro-Blue Tetrazolium Chloride) 
ng  Nanogram  
NK  Natural killer 
nm  Nanometers 
O.D.  Optical density 
PAGE  Polyacrylamid gel electrophoresis 
PBMC  Peripheral blood mononuclear cells 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PHA  phytohemaglutinine 
pM  Picomole 
POD  Peroxydase 
RNA  Ribonucleic acid 
RBA  Rose bengal assay 
rcIL-12 Recombinant canine Interleukin-12 
rcscIL-12 Recombinant canine single-chain Interleukin-12 
rpm  Revolution per minute 
  
Abbreviations                                                                                                                                             
 
rtTA  Reversed tetracycline-controlled transactivator 
sec.  Second(s) 
SDS  Sodium dodecyl sulfate 
Taq  Thermococcus aquaticus 
TBE  Tris-borate-EDTA buffer 
Tet  Tetracycline 
Th cell  T helper cell 
T  Thymidine  
TRE  Tetracycline responsive element 
tTA  Tetracycline-controlled transactivator 
U  Unit 
UV  Ultraviolet 
V  Volts 
v/v  Volume per volume 
VP16  Herpes Simplex virion partical protein 16 
w/v  weight per volume 
XTT  Na-3,3`-[1-(phenylamino)carbonyl-3,4-tetrazolium]-bis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
   
Introduction                                                                                                                                 1 
 
 
1 Introduction 
 
The pursuit to improve specificity of tumor therapy has driven tumor research over the last 20 
years. As a consequence, the tumor immunotherapy has now become one of the most 
extensively researched areas on the field of tumor therapy. Due to the great progress in basic 
research, numerous approaches based on cancer immunotherapy have evolved over the last 
decade. Generally, they can be classified into two different strategies: those that employ the 
constituents of humoral immunity, mostly antibodies, and those that make use of the cellular 
immunity. Among the latter, two main directions are eminent one exploiting the antigen-
specific cytotoxic T cells, whereas the other relies on natural killer (NK) cells. The advantage 
of NK cells in contrast to cytotoxic T cells is that they do not require prior contact with the 
antigen in order to eliminate it. Additionally, the cytotoxicity of NK cells can be enhanced by 
various stimuli, including several cytokines. In this context, previous results from our lab 
performed in dogs, as well as numerous studies in human and mice have shown an increase in 
anti-tumor activity of lymphokine-activated killer (LAK) cells (cytotoxic CD8+ T cells and/or 
NK cells) following stimulation with interleukin (IL) -2. Another cytokine known to stimulate 
T cells and especially NK cells is IL-12. Enhancement of the NK cell cytotoxic and other 
anti-tumor activities by IL-12 have been well documented in human and mice, but detailed 
investigations in dogs have not been carried out so far. Thus, detailed investigations of the in-
vitro effects of IL-12 on canine lymphocytes are of importance, before investigating its effects 
in vivo. However, under in-vivo conditions, cells are exposed to almost constant 
concentrations of IL-12, which differ from in-vitro experiments where the cytokine is 
supplied in defined intervals. In order to provide in vitro conditions, which would resemble 
the conditions found in vivo we sought to construct a cell line that could secrete IL-12 into its 
supernatant upon induction with Doxycycline. For this purpose, the cDNA sequence of the 
canine IL-12 genes was first cloned in a Tet-On vector carrying tetracycline inducible 
promoter, and was stably transfected into a baby hamster kidney (BHK) Tet-On cell line. This 
cell line contains already stably transfected protein known as reversed tetracycline-dependent 
transcriptional transactivator (rtTA). Its function is to bind to the tetracycline inducible 
promoter in the presence of tetracycline and hence to initiate the expression of the cloned IL-
12 gene. Instead of tetracycline, another drug of the same group, doxycycline, is commonly 
used for induction of gene expression. Consequently, this new cell-line can be used to 
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investigate the potential of constant and permanent IL-12 stimulation to enhance anti-tumor 
activities of lymphokine-activated cells. Due to certain characteristics of the IL-12 biology 
mentioned below, the IL-12 coding cDNA was constructed to code for a single-chain protein. 
Besides using the constructed BHK Tet-On cell line for in vitro stimulation of lymphocytes, 
the constructed vector carrying the IL-12 could also be applied in tumor immunotherapy, by 
means of gene delivery into the tumor itself. 
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2 Literature Overview 
 
2.1 DNA Cloning 
 
The amplification of given DNA fragments can be achieved in two different ways, either by 
polymerase chain reaction (PCR) or by a cell-based approach. In case of PCR (SAIKI et al., 
1985), the DNA fragment is amplified in vitro, using a purified enzyme (DNA-dependent 
DNA polymerase). In the cell-based approach, the DNA fragment is introduced into a cell, 
mostly in bacteria, due to their simple manipulation. Among bacteria, Escherichia coli is most 
widely used. For introduction of the DNA fragment into the cell various DNA sequences 
capable of self-renewal (vectors) are used. Vectors are either modified sequences of a viral 
genome, or plasmids. The plasmids are naturally occurring double-stranded circular DNA 
sequences found in bacteria, which multiply independently of the bacterial genome. Vector 
plasmids are derived from naturally occurring plasmids, by removing the unnecessary 
sequences and adding additional sequences needed for cloning. These necessary sequences 
are: one origin of replication, one selection marker and a multiple cloning site (SAMBROOK 
AND RUSSEL, 2001). The origin of replication (defined sequence of base pairs) allows 
plasmid replication in the host cell, whereas the selection marker is a gene coding for a 
protein which renders the host cell resistant to a given drug. The gene coding for ß-lactamase 
(ABRACHAM et al., 1940), an enzyme which inactivates ampiciline by cleaving, is the 
mostly used selection marker. Genes coding for enzymes that inactivate other antibiotics such 
as neomycin, kanamycin and puromycin are also in use. The multiple cloning site (MCS) is a 
nucleotide sequence that contains restriction sites for different restriction endonucleases. The 
restriction endonucleases (restriction enzymes) were discovered in bacteria where they serve 
as defense mechanism against bacteriophages (viruses infecting bacteria) by cleaving its 
genome. Restriction enzymes work by binding to defined stretches of nucleotide bases 
(restriction sites), following which they cleave them. Each restriction site is specific for one or 
several enzymes, and hence it can be cleaved only by it/them. With help of the restriction 
enzymes the plasmid, as well as the sequence of interest are cut and afterwards ligated using 
another enzyme called DNA  
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ligase. In this way, the gene of interest is integrated into the plasmid sequence. The plasmid 
vector containing the sequence of interest is then introduced (transformed) into bacteria which  
can be easily propagated. However, the process of DNA uptake is not a constitutive 
characteristic of bacteria, and hence chemical or physical methods are used to render them 
transiently passable for the plasmid vector. The most routinely used method is the CaCl2 
method, where bacteria are incubated on ice in presence of CaCl2, following which they are 
exposed to 42°C for short time (30-120 seconds). Since not all bacteria exposed to 
transformation acquire the plasmid, those that are transformed have to be selected from the 
non-transformed bacteria. This is achieved with help of the selection marker carried by the 
plasmid. Thus, when the bacteria are incubated in medium containing the appropriate drug 
(antibiotic), only the transformed bacteria survive. Subsequently, the transformed bacteria are 
grown in sufficient quantities and using chemical approaches the plasmid is isolated, after 
which it can be used in downstream applications.  
The vector plasmids used only for DNA amplification are also known as cloning vectors. 
When the vector is provided with a bacterial promoter, the protein coding sequence inserted 
downstream of it will be transcribed by the bacterial DNA-dependent RNA polymerase and 
consequently expressed. These vectors are named bacterial expression vectors and are used 
when the protein needs to be purified and further structurally or functionally investigated.  
 
2.2 Protein expression in mammalian cells 
 
2.2.1 General principles 
 
The need for correct protein folding and posttranslational modifications prevents the 
expression of many mammalian proteins in bacteria e.g. Escherichia coli (E. coli). It is known 
that some of the posttranslational modifications are unique to mammalian cells, so expression 
in bacteria does not lead to formation of a functional protein. For these reasons, such proteins 
must be expressed in mammalian cells by use of mammalian expression vectors. These 
vectors possess an appropriate mammalian promoter as well as a polyadenylation signal, 
which provides correct posttranscriptional processing of the mRNA molecule. Another 
important consideration when expressing a protein in mammalian cells is the mode of 
integration of its coding sequence into the recipient cell. In this regard, there are principally  
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two types of vectors used for mammalian expression. The first are viral-based vectors, 
predominately derived from adeno-associated viruses (AAV), which insert the sequence at 
specific sites on the chromosomal DNA. The second type can be any plasmid-based vector, 
whose characteristic is to enter the cell nucleus and integrate into chromosomes at random 
and with much lower efficiency than a viral-based vector. There are different opinions among 
scientists on how to improve chromosomal integration of non-viral vectors, but there is no 
single one that is widely accepted. Nevertheless, one method to improve chromosomal 
integration is the linearization of plasmid sequence, thus providing the wanted stable 
transfection. 
 
2.2.2 The Tet System for inducible mammalian expression 
 
When inserting an expression vector into the desired cell, the mode of regulation of gene 
expression is an important experimental issue. There are numerous vectors for expression in 
mammalian cells, offering various modes of transcriptional regulation. Thus, some of them 
utilize promoters providing strong and constitutive protein expression (e.g. CMV), whereas 
others are inducible. Among vectors carrying inducible promoters, tetracycline responsive 
element (TRE) - based vector is widely used. This vector was initially developed as a system 
that negatively regulates protein expression and hence called Tet-Off system (GOSSEN et al., 
1992). The Tet-Off system was adapted from elements controlling the expression of 
tetracycline resistance gene in bacteria. Here, regulatory nucleotide sequences (operator/ 
promoter) located upstream of the gene and a regulatory protein (tetracycline repressor) 
binding these sequences regulate its expression. Thus, in bacteria in absence of tetracycline, a 
repressor protein binds to the operator sequence and thereby prevents RNA polymerase from 
binding the promoter and activating transcription. Conversely, in presence of tetracycline, the 
repressor undergoes conformational changes and releases the operator, rendering the promoter 
binding site free for the polymerase to transcribe downstream genes. In the Tet-Off vector, 
seven copies of the tetracycline operator sequence followed by a minimal cytomegalovirus 
(CMV) promoter are placed 5’ to the sequence to be inserted. This order of sequences is 
called tetracycline responsive element (TRE). Protein expression from the TRE is controlled 
by a regulatory protein called tetracycline-controlled transactivator (tTA). tTA is a fusion 
protein of the first 207 amino acids of the tetracycline repressor and the C-terminal 127 amino  
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acids of the activation domain of VP16, which is herpes simplex virus encoded transcriptional 
activator. The addition of this activation domain to the Tet-repressor, together with the 
presence of the minimal CMV promoter (s.a.) in the TRE allows for start of transcription 
upon binding of the tTA to the TRE sequence. Consequently, in the Tet-Off system, in 
absence of tetracycline the tTA is bound to TRE and hence transcription of the downstream 
gene is provided. In contrast, upon tetracycline addition the tTA binds it, releasing the TRE, 
which consequently stops the transcription. To achieve convenient manipulation of protein 
expression, GOSSEN et al. (1995) modified the binding affinities of the tTA, so that in 
presence of tetracycline or its analogues, such as doxycycline, it binds to the operator 
(GOSSEN et al. 1995). This change was achieved by exchanging four amino acids in the 
tetracycline repressor and due to its “reverse” behavior the modified tTA was named reversed 
transcriptional transactivator (rtTA). 
This transactivator protein is stably transfected with help of an additional (helper) plasmid in 
a prior step, using neomycin resistance gene as selection marker. Expression of rtTA in the 
helper plasmid is controlled by the strong constitutive promoter pCMV, allowing constant 
expression of the rtTA. 
The Tet system offers more advantages compared to other inducible mammalian expression 
vectors, helping to improve the regulation of protein expression. Thus, YIN et al. (1996) 
reported that the Tet system provides very high expression levels, which are comparable to 
the levels obtained by strong constitutive promoters such as CMV. Another advantage of the 
Tet system is its high specificity, owing to the fact that the DNA regulatory elements 
controlling gene expression are found only in bacteria and hence they can not be influenced 
by the present mammalian regulatory proteins. 
 
2.3 Biology of IL-12 in human and mice 
 
As one of the most important cytokines in the T helper cells 1 (Th1) immune response, IL-12 
has been extensively investigated (GERMANN et al., 1993; STRAUSS-AYALI et al., 2005). 
Many studies have focused on the pro-inflammatory and anti-tumor effects of IL-12 
(KOBAYASHI et al., 1989; BRUNDA et al., 1993, GATELY et al., 1993). IL-12 is a 
heterodimeric cytokine of 70 kDa that is secreted predominantly by antigen-presenting cells 
(APC), especially dendritic cells (DC) (KOBAYASHI et al., 1989, GUBLER et al., 1991).  
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Various stimuli such as whole bacteria (Mycobacterium tuberculosis, Listeria spp., Neiseria 
meningitides etc.), IFN-γ plus LPS, lipoteichoic preparations of Gram-positive bacteria, and 
CpG motifs of bacterial DNA etc., can induce IL-12 secretion by the APC in-vitro as well as 
in vivo (D'ANDREA et al., 1992). IL-12 is composed of two subunits p40 and p35, named 
after their molecular weights (in kDa), and they are located on different chromosomes. The 
p35 subunit can be detected in non-stimulated cells, whereas p40 is expressed only in 
stimulated cells and significantly in excess to p35 (TRINCHIERI, 2003). In order for a 
functional IL-12 protein to be produced, both peptides must be expressed simultaneously in 
one cell (GUBLER et al., 1991). IL-12 exerts its actions by binding to its heterodimeric 
receptor, which consists of two subunits named IL-12 receptor beta1 (IL-12Rß1) and IL-12 
receptor beta2 (IL-12Rß2). IL-12 induced functions are mediated by its major downstream 
molecule, the transcription factor signal transducer and activator of transcription 4 (STAT4) 
(THIERFELDER et al., 1996). Regarding the biological activities of IL-12, it has been shown 
that: (1) it is the major cytokine driving the bias towards Th1 phenotype at the initial phase of 
the immune response by stimulating IFN-γ production (GERMANN et al., 1993); (2) it has a 
stimulatory role in the cytotoxic effector function of the NK cells and CD8+ T cytotoxic cells 
(CHEHIMI et al., 1992); and (3) it shows growth factor characteristics for T and NK cells 
(GATELY et al., 1991). Some of these effects, especially the cytotoxicity, are mediated by a 
number of molecules being up-regulated by target cells upon binding of IL-12 to its receptor. 
Among these molecules the most important are: IFN-γ, perforin (HASHIMOTO et al., 1999), 
Fas ligand FL (EBERT, 2004) and different adhesion molecules such as CD69, CD71, CD54, 
CD2 (RABINOWICH et al., 1993).  
IFN-γ. This signatory molecule of IL-12 stimulation is secreted by the two main IL-12 
responsive lymphocyte populations: T cells (Th1 and CD8+ cytotoxic T cells) and NK cells 
(CHAN et al., 1991). HODGE et al. (2002) have shown that in addition to regulation of IFN-γ 
on transcriptional level, IL-12 also confers post-transcriptional regulation of IFN-γ by 
stabilizing the nuclear fraction of its mRNA. Despite being one of the major Th1 cytokines 
and thus playing a predominant role against intracellular pathogens, IFN-γ has additional 
roles, for example in the immune response against cancer. This can be observed either 
through the direct action of IFN-γ on the cancer cells (DUNN et al., 2004) or indirectly 
through its anti-angiopoietic effects.  
 
 
 8  2   Literature Overview
 
Stimulation of cytotoxicity. In addition to the stimulation of IFN-γ production from NK 
cells, IL-12 was originally discovered for its stimulatory effects on the MHC-unrestricted 
cytotoxic activity of peripheral blood leukocytes (PBL) (KOBAYASHI et al., 1989). In the 
same study, it was shown that the CD3- CD5- CD56+ NK cell fraction represented the 
population of unfractionated PBL responsible for increased lymphokine activated killer 
(LAK) activity upon IL-12 stimulation. Following this discovery, a large amount of research 
was conducted in order to clarify the exact molecular action of the IL-12 induced cytotoxic 
activity of the lymphocytes. Hence, different molecules participating in the effector phase of 
the cytotoxic process, such as perforin (HASHIMOTO et al., 1999), granzymes (BONNEMA 
et al., 1994; DEBLAKER-HOHE et al., 1995) and TNF-α, were found to be up-regulated by 
IL-12. 
Lymphocyte proliferation. Another effect of IL-12 is its ability to stimulate proliferation of 
peripheral blood mononuclear cells (PBMC). A large amount of data exists on this topic, 
reporting on the effects of IL-12 on proliferation of the whole PBMC population, as well as of 
distinct lymphocyte fractions. Thus, IL-12 causes proliferation of PHA-stimulated 
lymphoblasts as well as proliferation of NK cells and of CD4+ and CD8+ T lymphocytes of 
such mitogen-stimulated PBMC (GATELY et al., 1991). Conversly, experiments 
investigating the proliferation of purified NK cells upon IL-12 stimulation showed that freshly 
isolated NK cells did not proliferate in response to IL-12 stimulation. Additionally it was also 
shown that IL-12 inhibited the IL-2 induced proliferation of pre-activated NK cells by 80-
90%. (ROBERTSON et al., 1992). 
IL-12 forms. All of the effects of IL-12 mentioned above are mediated through its 
heterodimeric IL-12 p70 form, but existence of other forms has also been reported among 
different species (GATELY et al., 1996; HEINZEL et al., 1997). The presence of additional 
forms of IL-12 is due to the fact that IL-12 p40 is expressed in excess compared to IL-12 p35 
(D’ANDERA et al., 1992) subunit, hence allowing formation of p40 homodimers and 
monomers. Nevertheless, the excess of the IL-12 p40 subunit shows different patterns of 
molecular interactions depending on the species. Additionally, different patterns of molecular 
interactions were also observed, depending on whether primary cells or transfected culture 
cells were investigated. Thus, immunoprecipitation of IL-12 p40 from human primary 
dendritic cells (DC) stimulated to produce IL-12, showed that p40 co-precipitated with the 
p35 chain only and not with another p40 chain. This confirmed that IL-12 p40 in human is 
expressed only as a monomer (CARRA et al., 2000). In contrast to primary cells, cells  
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transfected with plasmid carrying the human IL-12 cDNA showed presence of p40 
homodimers. This homodimeric form exhibited significantly lower binding affinity for the IL-
12Rß1 than the IL-12 heterodimer (CARRA et al., 2000). Nevertheless, due to over-
expression of the p40 subunit, p40 homodimers compete with the p70 heterodimeric form for 
the IL-12 receptor and hence act as an antagonist. This was shown by MATTNER et al. 
(1993) and LING et al. (1995) who demonstrated inhibition of IL-12 p70 induced lymphocyte 
proliferation by the p40 homodimeric form. In contrast to human primary cells, murine IL-12 
producing primary cells revealed the existence of IL-12 p40 homodimers, which are an 
effective antagonist of the biological action of murine IL-12 p70 heterodimeric form 
(HEINZEL et al., 1997). The absence of any biological, agonistic or antagonistic activity was 
demonstrated for the porcine IL-12 p40 homodimer (FOSS, 1999). 
IL-12 in tumor therapy. The anti-tumor activity of IL-12 has been confirmed by in vivo 
experiments in mice (BRUNDA et al., 1993). This has made IL-12 an attractive tool for anti-
cancer therapy following delivery to tumor patients. Among the studies performed, different 
ways of application (local, systemic), as well as different forms of IL-12 (cDNA, protein) 
have been investigated in their potential to reduce tumor growth or even to eradicate 
established tumors. Thus, some of these studies showed that intra-tumoral injection of 
adenoviral vector encoding the IL-12 cDNA induced complete regression of several different 
tumors experimentally established in mice. These tumors include subcutaneous murine 
adenocarcinomas and fibrosarcomas (GAMBOTTO et al., 1999), breast (BRAMSON et al., 
1996) and colorectal carcinoma (MAZZOLINI et al., 1999), orthotopically implanted murine 
tumors including medullary thyroid carcinoma (NASU et al., 1999) and hepatocellular 
carcinoma (BARAJAS et al., 2001). Additionally, some of these studies (GAMBOTTO et al., 
1999) also reported rejection of subsequent rechallenge with the same tumors, indicating a 
persistence of a long lasting anti-tumor immunity. In contrast to gene delivery studies, there 
are no studies investigating the potential of in vitro IL-12 stimulated, adoptively transferred 
lymphokine activated killer (LAK) cells, despite the well investigated IL-12 stimulative effect 
on T cell mediated and especially on NK cell mediated cytotoxic activity. Hence, studies 
investigating the potential of using adoptively transferred LAK cells for cancer 
immunotherapy are needed. 
 
 
 
 10  2   Literature Overview
 
2.4 Biology of IL-12 in dog 
 
Canine IL-12 was cloned independently by two groups (OKANO et al., 1997; BÜTTNER et 
al., 1998) and it was shown that both subunits have more than 80% identity with IL-12 of 
several other species (human, mouse, bovine), as determined by computer-aided sequence 
comparison (BÜTTNER et al., 1998). In accordance with the structural similarity, the 
biological activities of the canine IL-12 proved to be similar to those described for the 
respective human and murine counterparts. Because of this, the biological activities of canine 
IL-12 were investigated mostly in clinical studies in dogs infected with Leishmania species 
(STRAUSS-AYALI et al., 2005). Apart from this study there are only a few other studies that 
have investigated the biological activities of IL-12 in dogs. Thus, PHILLIPS et al. (1999) 
have demonstrated an increased proliferation of canine phytohemaglutinine (PHA)-
lymphoblasts as well as an increased cytotoxic activity of freshly isolated canine PBMC after 
3 days stimulation, but using human recombinant IL-12. Although this group has 
demonstrated biological effects of human IL-12 on canine lymphocytes, its use in cancer 
immunotherapy is connected with the risk of initiating antibody response in dog. Another 
group working with canine IL-12 (SALDARRIAGA et al., 2006), investigated the increase of 
the IFN-γ mRNA level upon stimulation with canine IL-12 fused heterodimeric cDNA (single 
cDNA coding for the both IL-12 subunits). They also showed that in vivo application of the 
fused heterodimeric IL-12 cDNA had the same effects regarding the increase in the IFN-γ 
mRNA level. However, other effects like proliferation or cytotoxic activity of the canine 
PBMCs, or of their subpopulations have not been investigated.  
 
2.5 IL-12 as a single chain  
 
Considering the facts about the IL-12 biology mentioned above and the interest of introducing 
its nucleotide sequence into the tumor site as an effective tumor therapy, the construction of a 
single plasmid carrying the both IL-12 subunits has emerged as convenient solution. This 
plasmid offers a solution to overcome the disadvantages that accompany gene therapy where 
both subunits are transfected on separate plasmids. Exemplarily, one of the drawbacks in 
applying the IL-12 sequence to a patient is the fact that functional IL-12 requires the presence 
of both chains in the same cell (GUBLER et al., 1991).  
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Since transfection is a very random process, a double transfection with two different plasmids 
lowers the chances for a successful outcome. Additionally, gene therapy is accompanied by 
certain risks, because the heterogenic genetic material is introduced into the patient. This is 
specially to be regarded when delivering the sequence with help of viral vectors, some of 
which potentially confer their own threat for the patient. The first attempt to overcome these 
problems resulted in construction of a IL-12 cDNA sequence inserted into a retroviral 
construct, where an internal ribosomal entry site (IRES) element from the 
encephalomyocarditis virus was used for separate translation of each of the subunits 
(ZITVOGEL et al., 1994). Although the vector was successfully transfected, this approach 
showed a drawback in the progressive reduction of the expression rate downstream of each 
IRES. In this case the difference in the expression rate of the two subunits makes the 
formation and thus the activity of the IL-12 heterodimer less predictable and less reproducible 
between experiments. As a solution, a single nucleotide sequence encoding both p40 and p35 
subunits connected by a linker sequence, was constructed by ANDERSON et al. (1997). The 
linker sequence encodes a decapeptide chain containing two elastin motifs. It adopts its 
structure in such a way that it does not intervene with the formation of intra- and interpeptide 
structures of both IL-12 subunits, thus allowing to form the natural conformation. 
 
2.6 Investigation of the IL-12 effects on PBMC 
 
2.6.1 PBMC Isolation 
 
The most widely used technique for routine separation of peripheral blood cells is density 
gradient centrifugation, based on the different specific densities of cells. Numerous media 
suitable for this purpose have been described, with Ficoll® being the first choice due to its 
simple handling and pre-adjusted osmolarity. Another often used density centrifugation 
medium is the colloidal silica solution, Percoll® (Pharmacia, Sweden), with particles of a 
diameter of 15-30 nm and slightly hypoosmotic in comparison to the blood. The 
hypoosmolarity of Percoll® can be easily corrected by adding 1 part of 1.5 N NaCl solution to 
9 parts of the Percoll® stock solution. Because of the difference in densities among 
lymphocyte populations in different species precise determination of the conditions for 
isolation of PMBC from the blood must be performed for every species. Thus, an optimal  
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medium for isolation of canine PBMC is Percoll®, which showed better results in comparison 
to Ficoll® (GONDOLF, 1994; GONDOLF et al., 1996). The most appropriate concentrations 
for isolation of different sub-fractions of the canine PBMC using Percoll® were determined in 
our lab (GONDOLF, 1994; GONDOLF et al., 1996). According to these results 58.5 % 
Percoll® working solution, allows isolation of PBMC fraction enriched in NK cells. 
 
2.6.2 Cytotoxicity assay 
 
The Chromium-Release Assay (CRA) has been widely used as a gold standard for 
investigating the cytotoxic activity. This assay analyses the release of radioactive 51Cr from 
labeled target cells into the supernatant. The subsequently measured radioactivity in the 
supernatant is analogous to the cytolysis of target cells caused by a given agent. However, the 
need for special precautions when working with the CRA and its high price are significant 
disadvantages. As an alternative to the CRA, a new non-radioactive colorimetric method for 
determining the cytotoxic activity against adherent target cells using Rose-Bengal color was 
established in our department (GONDOLF 1994, GONDOLF et al., 1996). The Rose-Bengal 
Assay (RBA) is based on the loss of adherence of the killed (dead) target cells. To determine 
this, target cells are plated in a 96-well plate and incubated until they form a monolayer, after 
which effector cells are added at various effector to target (E:T) ratios. The effector and target 
cells are incubated in a co-culture allowing direct contact between them. As negative controls 
monolayers without effector cells are used. Following incubation, the supernatant together 
with the effector cells and the non-adherent dead target cells are removed from the wells. The 
remaining target cells are incubated with the Rose-Bengal color allowing them to absorb it. 
Following incubation, the color is released into the supernatant by an ethanol-containing 
solution. The intensity of the color in the supernatant is determined by measuring its optical 
density (O.D.) in a spectrophotometer at 570 nm, using the 630 nm for a background 
correction. Among the adherent target cells, canine thyroid adenocarcinoma (CTAC), as NK-
sensitive and VERO as NK-resistant cell lines were investigated by GONDOLF (1994, 1996). 
Experiments showed that the formation of a target cell monolayer is best obtained after 26 
hours, if plated at a density of 1x104/well. Furthermore, the investigation of different 
incubation times of effector and target cells showed that 14 hours are optimal for obtaining 
reliable results.  
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Important advantage of RBA over the CRA is the fact that CRA allows measuring of 
cytotoxic processes due to cell membrane disruption only. Since the apoptotic processes are 
lacking cell membrane disruption, the detection capacity of CRA is limited only to necrotic 
processes, excluding detection of apoptotic events. In contrast, both necrotic and apoptotic 
events lead to loss of cell adherence, making RBA more sensitive then the CRA (GONDOLF 
1994, GONDOLF et al., 1996). 
 
2.6.3 Cell proliferation 
 
Cell proliferation is one of the criteria widely used to determine cell activity, response to 
stimulation and its physiological state. The various assays used for measuring cell 
proliferation can be divided into two groups: (1) assays such as MTT, XTT and Alamar Blue 
which indirectly analyze proliferation by measuring the metabolic activity of cells; (2) assays 
that directly determine the newly synthesized DNA, using radioactive labeled nucleotides, as 
in [3H]-thymidine incorporation assay (TdR), or non-radioactive labeled nucleotides, as in 
Bromodeoxyuridine (BrdU) incorporation assay. Another possibility to directly confirm the 
mitotic activity is the measurement of total DNA increase using different nucleophilic 
fluorescent dyes, which can be quantified using flow cytometry. Because of the simplicity in 
handling, the use of non-radioactive materials and lower cost, the ELISA based BrdU method 
(WAGNER 1998, WAGNER et al., 1999) was used to investigate the proliferation of canine 
PBMC. In this approach, cells are incubated with BrdU in presence of the appropriate 
stimulus for the required time. During the incubation time the cells entering mitosis 
incorporate the BrdU, whereas the resting cells do not. Afterwards the cells are centrifuged, 
fixed and permeabilized. In this way the incorporated BrdU is ready for detection by a 
specific peroxidase (POD) labeled anti-BrdU antibody. In the following step H2O2 based 
peroxidase substrate is added to the wells and the reaction mix is incubated for up to 30 
minutes. The peroxidase activity is stopped by adding H2SO4 after which the O.D. of each 
well is determined in a spectrophotometer at 450 nm wavelength, using the wavelength of 630 
nm for background correction.  
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3 Materials and Methods  
 
3.1 Cloning  
 
3.1.1 Polymerase chain reaction (PCR) 
 
3.1.1.1 KOD Hot Start DNA Polymerase  
 
When a reliable amplification of the sequences of interest was required, KOD Hot Start DNA 
Polymerase (Novagen®) with 3’→5’ “proof-reading” activity was used. PCR with this 
polymerase was performed according to the manufacturer’s recommendations. Shortly, the 
PCR was performed in a 50 µl reaction volume in presence of 1x buffer for KOD Hot start 
DNA Polymerase, 0.2 mM dNTPs (final concentration each), 1mM MgSO4, 10 pM of each 
primer (MWG) and 1U KOD Hot start DNA Polymerase. Depending on the aim of a given 
PCR reaction, different amounts of DNA were used as a template. For site-directed 
mutagenesis 5-15 ng template plasmid DNA was used, while 30 ng were used where genomic 
DNA served as a template. The PCR program was set as follows:  
 
1. Initial denaturation at 94°C for 2 min. 
2. Cyclic denaturation at 95°C for 15 sec. 
3. Annealing step 30 sec.: 
- for site-directed mutagenesis 60°C was used  
- for every other purpose the optimal temperature was determined by a gradient PCR 
4. Extension 1min/kb at 68°C  
5. Final extension 5min at 68°C  
 
After each PCR performed, the product of interest was analyzed by gel electrophoresis and 
further processed according to the requirements of the subsequent experiment.  
 
 3   Materials und methods         15 
 
 
 
3.1.1.2 Taq Polymerase 
 
PCR reactions that did not require the “proof-reading” activity of the polymerase were 
performed with Taq Polymerase (PeqLab), according to the manufacturer’s instructions. 
These PCR reactions were performed in 25 µl reaction volume, 1X buffer for the Taq-
Polymerase (1.5mM MgCl2), 0.2 mM dNTPs (final concentration each), 10 pM of each 
primer and 2,5 U Taq-Polymerase. Depending on the source of the DNA, the appropriate 
amount of template was used. The PCR program used with the Taq Polymerase was as 
follows:  
 
1. Initial denaturation at 94°C for 2:30 min.  
2. Cyclic denaturation at 92°C for 30 sec.  
3. Annealing step 30 seconds: 
- the optimal temperature was determined by a gradient PCR for each primer pair 
4. Extension1 min/kb at 72°C 
5. Final extension 5min at 72°C 
 
3.1.1.3 A-overhang addition and TA cloning 
 
The A-addition kit (Qiagen) was used for adding the adenine nucleotide on the 3’ end of the 
DNA fragments with blunt ends, obtained after amplification with KOD Hot Start 
Polymerase. For this purpose, 5 µl of the PCR reaction volume were taken immediately after 
the amplification and incubated with 2µl of the 5X A-addition master mix (Qiagen) and 3µl 
ddH2O in a total volume of 10µl, at 37°C for 30 min. Following incubation, an aliquot of this 
reaction was inserted into the pGEM-T® cloning vector (Promega), as recommended by the 
manufacturer. Shortly, 5 µl of the 2X rapid ligation buffer (pGEM-T® Vector System I kit, 
Promega), 1µl of the pGEM-T® vector, 1µl of the T4 DNA Ligase (3 Weiss units/µl, pGEM-
T® Vector System I kit, Promega), and 3 µl of the fragment taken directly from the A-addition 
reaction volume were incubated at 4°C overnight, identically as described for the other 
ligation reactions (3.1.4). Following ligation, the ligation production was transformed into E. 
coli (HB101) as described (3.1.5). 
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3.1.2 Gel electrophoresis 
 
After each PCR, the size of the amplicons was confirmed on polyagarose electrophoresis. 
Depending whether the amplicon had to be isolated, or only confirmed on gel, different 
agarose (SeaKem LE Agarose, Lonza) concentrations were used. Thus, 0.8% agarose was 
used for isolation of the amplicons, since most of them were larger then 1kb. In one case 
where the product was 200 bp, a 2% agarose gel was used. For detection purposes 1-2% 
agarose was used, depending on the expected product size. For preparing of the gel, which 
was cast in a small (6x10 cm) chamber, the agarose was dispersed in 1xTBE buffer and 
heated in a microwave oven until completely dissolved. Before casting the gel, ethidium 
bromide was added to the agarose. Five parts of each amplification reaction were mixed with 
one part of a 6X loading dye (6X loading dye solution, Fermentas) and loaded into gel slots. 
The electrophoresis was run using power supply system (Consort E425) at 80 V/cm/h in 1x 
TBE buffer. The PCR products resolved in the gel were visualized under exposure at 254 nm 
UV light (UV-lamp, Bachofer) and documented using the EDAS 120 system (KODAK). 
 
3.1.3 Restriction digestion  
 
Different restriction enzymes were used to digest the different sequences needed to create 
rcscIL-12. As a general rule, the restriction digestion was carried out in 60 µl volume, using 
between 3-6 µg of the DNA sequence to be digested, but always in equal molar ratios. 
Following the general principles of the restriction digestion, 1x of the corresponding buffer 
was used, whereas the restriction enzyme was applied at concentration of 1U pro 1µg of target 
DNA. All restriction digestions were performed at 37° C for 1 hour, except for the BsmBI 
enzyme (NEB), when 55°C was used. Where double digestion was not feasible due to the 
incompatibility between some buffers and enzymes, the DNA was consecutively digested. 
Thus, following the digestion with the first enzyme the DNA was “cleaned-up” using 
commercially available DNA binding columns (Macherey Nagel) as recommended by the 
manufacturer. For this purpose, the reaction volume after the first digestion was applied on  
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DNA binding column, which was centrifuged for 2 min at 7000 rpm in a microcentrifuge, and 
the flow-through discarded. The bound DNA was eluted from the column with 40 µl ddH2O 
and was used for the second digestion, again in a volume of 60 µl. The digested fragments 
were gel electrophoresis purified and isolated using a commercially available gel removal 
column (Nucleo Trap® Extraction kit, Macherey Nagel). For this purpose, the reaction volume 
of the digested DNA was loaded onto a 0,8% gel, the electrophoresis run at 80 V in 1x TBE 
buffer for 1h, the gel was visualized under 254nm UV light (UV-Lamp, Bachofer) and 
documented using EDAS 120 system (KODAK). The fragment of interest was cut out and 
transferred onto the appropriate column, which was centrifuged at 7000 rpm for 2 min. The 
eluate containing the DNA fragment of interest was further used in the corresponding ligation 
reaction.  
 
3.1.4 Ligation  
 
For the purpose of ligation, the fragments of interest were incubated together in an equal 
molar ratio in the presence of 1U of E.coli DNA Ligase at 4°C overnight. The ligation product 
was either transformed into E. coli in the case of plasmids or was used as a PCR template 
when further manipulation was necessary.  
 
3.1.5 Transformation of E.coli 
 
When a further amplification of a desired plasmid was needed, the plasmid was transformed 
into E.coli cells (HB101, K12 strain). For this purpose, the bacterial cell suspension (50 µl) 
was thawed on ice for 8-10 minutes and afterwards the appropriate plasmid containing 
reaction volume was added, followed by an additional incubation of 20 minutes on ice. As a 
next step the cells were “heat-shocked” at 42°C for 2 min followed by an additional 
incubation on ice for 2 minutes. 100 µl LB (Roth) medium were added and the entire content 
was spread out onto a Petri-dish (82 mm diameter) containing LB (Roth) agar supplied with 
50µg/ml ampicilin (Roth). Depending on the actual purpose of the cloning, the selection was 
done with help of the white-blue screening, when using plasmids carrying the gene for ß-
galactosidase. The LB agar containing plates used for blue-white screening were supplied  
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with 40µg/ml X-Gal (Roth) and 50µg/ml IPTG (Roth). Otherwise, when using plasmids not 
carrying the ß-galactosidase gene, random picking of 10 colonies was performed. In both 
cases the selected clones were cultured overnight in LB medium containing ampicilin 
(50µg/ml). The transformed colonies were identified by means of a colony PCR with a crude 
bacterial lysate serving as a template. 
 
3.1.6 Plasmid DNA extraction 
 
The colonies positive in colony PCR were used for plasmid extraction using column 
chromatography-based plasmid preparation kit (NucleoSpin® Plasmid, Macherey Nagel) 
according to the manufacturer’s recommendations: 
 
1. The bacterial cell suspension was grown in 10 ml LB medium at 37°C for 14-16 
hours. 
2. After the incubation time the bacterial cells were pelleted at 11.000 x g for 2 minutes, 
the supernatant removed and the bacterial cell pellet resuspended in 250 µl of the 
appropriate resuspension buffer (buffer A1). The resuspended cells were vortexed in 
order to resuspend any remaining clumps. 
3. 250 µl of a sodium dodecyl sulfate (SDS) containing lysis buffer (A2) was added to 
the cell suspension and the tube was gently inverted to allow complete lysis.  
4. 300µl of the A3 buffer were added to the lysate, allowing the proteins to further 
denaturate and precipitate. At the same time this buffer creates optimal conditions for 
DNA binding to the NucleoSpin column.  
5. The lysate was centrifuged at 11.000 x g for 5-10 minutes and the DNA containing 
supernatant was transferred onto the column.  
6. The column was incubated for 1-2 minutes to allow the DNA molecules to bind and 
then it was centrifuged in a microcentrifuge at 11.000 x g for 1 min. 
7. After the flow-through was discarded, 600 µl of ethanol containing buffer (A4) were 
added to the column to remove the contaminants like salts, metabolites and soluble 
macromolecular cellular components. The column was centrifuged  at 11.000 x g for 1 
minute. 
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8. The flow-through was discarded again and the column was centrifuged additionally at 
11.000 x g for 2 min. in order to dry the silica membrane completely.  
9. After drying 50 µl of the elution buffer (AE) providing low ionic and slightly alkaline 
conditions (5mM Tris-Cl, pH 8.5) were added to the column and it was incubated at 
RT for 1 min. 
10.  The eluted plasmid DNA was collected by centrifugation at 11.000 x g for 1 min. and 
the eluate was transferred to a new tube.  
 
The plasmid DNA concentration was determined after every isolation procedure using an UV 
spectrophotometer (UV-1202, Shimadzu) at 1:1000 dilution of the plasmid DNA solution 
with molecular grade H2O. 
 
3.2 Construction of the recombinant canine single chain IL-12 (rcscIL-12) 
 
3.2.1 Completion of the cDNA coding for the IL-12 p35 sequence 
 
The sequences coding for the canine IL-12 p35 and IL-12 p40 subunits (BÜTTNER et al., 
1998) were kindly provided by Prof. Dr. Mattias Büttner (“Landesamt für Gesundheit und 
Lebensmittelsicherheit Oberschleißheim”, Germany). Because of the time spent at -20°C 
confirmation of the sequences was performed by sequencing at MWG Biotech (Ebersberg, 
Germany). The sequencing results showed that the sequence coding for p35 contained the in-
frame sequence of the first six exons (bp 1-494), with exception of the last 20 nucleotides of 
exon six (bp 494-514). Additionally, the complete seventh exon (bp 515-669) was also absent 
and hence the addition of the bases 494-669 to the existing sequence of the first six exons was 
required in order to complete the p35 subunit. For this purpose, the missing exon 7 was 
amplified from genomic DNA, using the following primers: forward primer 5’ 
cgtctcagccctgaatttcaacagtgtgact 3’; reverse primer 5’acgcgtttaggaagaattcagataactcatcattc 
tatcgatggtcaccg 3’. This PCR reaction was performed under conditions described for KOD 
Hot Start DNA Polymerase. The rest of the sequence, from exons 1 to 6, which existed in the 
plasmid provided by Prof. Dr. Büttner (s.a.) was also multiplied by a PCR reaction as 
described (1.1.1.), using the following primers: forward primer 5’atgtgcccgccgcgcggcctcc 3’ 
and 5’cgtctccgggcctgtaacagctcatcgatagctgtcaacatgttttgatccaga 3’ as a reverse primer. For the  
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purpose of connecting these two fragments, BsmBI restriction sites (cgtctcxxxx) were 
introduced in the reverse primer for the exon 1-6 sequence and in the forward primer for the 
exon 7 sequence. After the sequences had been confirmed by sequencing (MWG), they were 
reamplified, digested with the BsmBI enzyme and ligated together (3.1.4). The ligation 
product was used as PCR template in the next reaction in order to re-amplify the complete 
p35 sequence using the forward primer for exon 1-6 sequence and the reverse primer for the 
sequence of exon 7. This amplicon was isolated and ligated into a plasmid vector as described 
above. After the positive clone had been chosen, it was sent for sequencing to MWG and its 
sequence confirmed. 
 
3.2.2 Correction of the p40 Sequence (DpnI site-directed mutagenesis) 
 
The sequencing of the plasmid containing the cDNA coding for the p40 subunit revealed the 
sequence presented in fig. 1. Positions 375 and 826, shown as capital letters, did not match the 
published consensus sequence of p40 (PubMed Acc.Nr.:NM_001003292). Thus, at position 
375 a surplus adenine (A) was detected rendering the nucleotide sequence out of frame and at 
position 826 an adenine was confirmed instead of guanine (G). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1   atgcatcctcagcagttggtcatctcctggttttccctcgttttgctggcgtctcccctc 60                                                                        
   61  atgaccatatgggaactggagaaagatgtttatgttgtagagttggactggcaccctgat 120                                                                      
   121 gcccccggagaaatggtggtcctcacctgccatacccctgaagaagatgacatcacttgg 180 
   181 acctcagcgcagagcagtgaagtcctaggttctggtaaaactctgaccatccaagtcaaa 240 
   241 gaatttggagatgctggccagtatacctgccataaaggaggcaaggttctgagccgctca 300 
   301 ctcctgttgattcacaaaaaagaagatggaatttggtccactgatatcttaaaggaacag 360 
   361 aaagaatccaaaaaAtaagatctttctgaaatgtgaggcaaagaattattctggacgttt 420 
   421 cacatgctggtggctgacggcaatcagtactgatttgaaattcagtgtcaaaagtagcag 480 
   481 aggcttctctgacccccaaggggtgacatgtggagcagtgacactttcagcagagagggt 540 
   541 cagagtggacaacagggattataagaagtacacagtggagtgtcaggagggcagtgcctg 600 
   601 cccctctgccgaggagagcctacccatcgaggtcgtggtggatgctattcacaagctcaa 660 
   661 gtatgaaaactacaccagcagcttcttcatcagagacatcatcaaaccagacccacccac 720 
   721 aaacctgcagctgaagccattgaaaaattctcggcacgtggaggtcagctgggaataccc 780 
   781 cgacacctggagcaccccacattcctacttctccctgacattttgcAtacaggcccaggg 840 
   841 caagaacaatagagaaaagaaagatagactctgcgtggacaagacctcagccaaggtcgt 900 
   901 gtgccacaaggatgccaagatccgcgtgcaagcccgagaccgctactatagttcatcctg 960 
   961 gagcgactgggcatctgtgtcctgcagttaggttccacccccaggatgaatcttgg 1016 
 
Fig 1: IL-12 p40 sequence as obtained 
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In order to correct these mismatched bases, these positions were consecutively replaced using 
DpnI mutagenesis approach. For this purpose the plasmid carrying the cDNA coding for p40, 
was completely amplified by PCR using KOD Hot start polymerase, (3.1.1.1) with the 
appropriate primers (position 375: forward primer 5` ggaacagaaagaatccaaaaataagactttt 
ctgaaatgtg 3`; reverse primer5`cacatttcagaaagatcttatttttggattctttctgttcc 3`; position 826 
forward primer 5`cttctccctgacattttgcgtacaggcccagggcaagaac 3`, reverse primer 
5`gttcttgccctgggcctgtacgcaaaatgtcagggagaag 3`). The PCR amplicon was digested with DpnI 
at 37°C for 1h. Following digestion the sample was used to transform E.coli as described 
(3.1.5) and the plasmid was subsequently isolated. The isolated plasmid was sent to 
sequencing in order to confirm that the change of interest has occurred.  
 
3.2.3 Construction of the rcscIL-12 
 
In order to bring both IL-12 subunits (p35 and p40) together, they were reamplified using the 
following primers: p40 forward primer 5’ ggtaccatgcatcctcagcagttggtc 3’; p40 reverse primer 
5’ cgtctcaggacaccgactcccgggacactgcaggacacagatgcccagtc 3’; p35 forward primer 5’ 
cgtctcggtcccaggtgtcggtatgtgcccgccgcgcggcctcc 3’; p35 reverse primer 5’ 
acgcgtttaggaagaattcagataactcatcattctatcgatggtcaccg 3’. After the PCR had been performed, 
the amplicons were double digested with the following enzymes: p40 was initially digested 
with KpnI at 37°C for one hour in one for all (OFA) buffer, followed by digestion with 
BsmBI at 55°C for one hour. Similarly, the p35 was digested with PstI at 37°C for one hour in 
the NEBuffer 3 and afterwards with BsmBI at 55°C for an additional hour. The resulted 
restriction fragments were separated using gel electrophoresis and the sequences were isolated 
from the agarose gel. The fragments were ligated using the E.coli DNA ligase at 4°C over 
night, and 1µl of the ligated product was used as a template for a PCR performed under 
conditions for KOD Hot Start Polymerase with the p40 forward and p35 reverse primers. The 
resulting PCR product was cloned into pGEM-T (Invitrogen) vector as described previously. 
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3.2.4 Construction of the sccIL-12-IRES/Lucifease-pTRUE plasmid 
 
For the purpose of creating this construct the sequences needed were digested at concentration 
of 3µg/ml in the appropriate buffers. Thus, the pTRUE vector (derived from pTRE, 
Clontech®, personal communication: PD Dr. Tautz, University of Luebeck, Germany) was 
consecutively digested with SacII and PstI (NEB®) due to the incompatibility of the two 
enzymes for a simultaneous digestion. The digestion was first performed with SacII enzyme 
in the presence of NEBuffer 4 buffer for two hours followed by a step of buffer removing 
using a DNA binding column. Afterwards the SacII-linearised pTRUE vector was digested 
using the PstI enzyme in the H-Buffer (TaKaRa®) for an additional hour. After digesting the 
pTRUE vector, it was dephosphorylated in presence of 1µl of a calf intestinal alkaline 
phosphatase at 37°C for 5 min. Similarly, the sequence coding for the rcscIL-12 was also 
consecutively digested with SacII and MluI enzymes (NEB®) under the same conditions as 
for SacII (s. a.), followed by a step of a buffer removal. The linearized rcscIL-12 vector was 
digested with the MluI enzyme in the NEBuffer 3 for one hour. The IRES/Luciferase cassette 
was double digested with MluI and PstI in the NEBuffer 3 for one hour. These three 
restriction fragments were isolated from a preparative 0.8 % gel, and following isolation they 
were ligated at 4°C in a presence of 1 x ligase buffer and 1U of E.coli DNA ligase over night. 
The resulting ligation product was transformed into E.coli cells (s. a.). 
 
3.3 Establishing of a stably transfected BHK-Tet-On cell line 
 
3.3.1 Stable transfection 
 
The stable transfection of the BHK-Tet-On cell line with the sccIL-12 carrying plasmid was 
performed using lipofection. The sccIL-12 construct (s. 1.3.1) was previously cloned in E. 
coli (s.1.3.3). After a column chromatography was applied for purification, its concentration 
was determined using UV-spectrophotometer. Total amount of 6 µg of the plasmid was 
linearized at 37°C in the presence of 1 x buffer and in a total volume of 60 µl for 1 hour. 
Thereafter, 3 µg of the linearized construct (10 µl of the 300 ng/µl plasmid solution) was 
added to 10 µl of the liposome solution (Lipofectamin®, Qiagen) and 70 µl medium without  
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serum and the mixture was incubated at room temperature for 10 minutes. Together with the 
linearized construct containing the IL-12 gene, another one, also linearized vector coding for 
Puromycine resistance (personal communication PD Dr. Tautz, University of Luebeck, 
Germany) was added to the mixture at a concentration 100 times lower (3ng/ml) than the 
concentration of the rscsIL-12 containing plasmid. This transfection mixture was added to the 
BHK Tet-On cells (previously grown to confluence in a 6-well plate overnight) and these 
were incubated for two hours. Following incubation, the transfection mixture was removed 
and RPMI (PAA, Austira) culture medium containing 10% serum was added to the cells in 
order to incubate them for an additional 24 hours. 
 
3.3.2 Cloning of the transfected cells 
 
After 24 hours of incubation, the stably transfected cells were completely trypsinized and 
transferred to a 10 cm Petri dish containing 10 ml of complete medium supplied with 1µg/ml  
Puromycine dihydrochloride (Alexis corporation) and 0.4 mM neomycin sulfate (G418, 
Amresco). From this Petri dish further 10-fold serial dilutions were made (from 1: 10 to 1: 10. 
000) in the same medium, in final volumes of 10 ml. On the following days the development 
of, as good as possible from one another separated areas, or cell isles was monitored in every 
dish. From the dilution with most distinctly separated cell isles, ten were randomly selected, 
carefully trypsinized and transferred into separate wells of a 24-well plate. They were allowed 
to grow to confluence and those populations forming monolayers were brought to 10-cm 
Petri-dishes. After they had grown to confluence in Petri-dishes, they were further subcultured 
and two portions of 1 x 106 cells of each population were concomitantly used for luciferase 
assay. One of the portions was incubated with Doxcycline, while the other one was left 
without, serving as a negative control. After the luciferase assay was performed, the best two 
populations according to the absolute values of the luciferase assay and the induction index 
(the difference between the Doxycycline induced and non-induced cells), were further 
subcloned using limited dilution cloning. The resulting clones were again tested for luciferase 
activity as described (3.3.3). The two clones with the highest luciferase assay values in the 
first subcloning underwent a second subcloning procedure.  
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3.3.3 Luciferase assay 
 
The luciferase assay was performed with duplicate portions of 1x106 cells were cultured at 
37°C, 5%CO2 in a 6-well plate overnight. On the next day they were lysed according to the 
following protocol:  
 
1. The medium was flicked off. 
2. The cells were washed with 1X PBS solution.  
3. The cells were incubated with 400 µl/well of the 1X lysis buffer, and after the cell 
layer had been gently scraped, the resulting cell lysate was transferred into 1.5ml 
Eppendorf tubes. These were stored on ice until further use.  
 
For measuring the luciferase activity with the Luciferase Assay System kit (Promega), 20 µl 
of every cell clone lysate were incubated with 100µ of the 1X luciferase substrate (Luciferase 
Assay System, Promega). The resulting light emission was detected in a luminometer and was 
expressed as absolute value. 20µl PBS were used as a blank, and these values were withdrawn 
from the values of the probes. All probes were measured in duplicate and their mean was 
calculated. The values of the Doxycycline induced cells and of cells incubated without 
Doxycycline were compared, with their ratio serving as a measure for the Luciferase 
inducibility by Doxycycline (induction index).  
 
3.3.4 Immunofluorescence 
 
The cells of both finally chosen clones were cultured in duplicates in 6-well plates at 
concentration of 1x106cells/ml overnight. One of the duplicates of each cell clone was 
cultured in presence of doxycycline, whereas the other one was cultured without it. On the 
next day the cells were processed as follows: 
1. The medium was removed.  
2. The cells were washed with 1ml PBS pro well. 
3. The cells were fixed by incubation in 750 µl methanol-aceton solution (1:1 pre-mixed 
solution, cooled at -20°C) at - 20°C for 20 min. 
4. The methanol-aceton solution was removed and the cells were air-dried. 
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5. The cells were re-hydrated with 750 µl/well of the PBS/Tween solution at room 
temperature for 1 min. 
6. The cells were washed with 750 µl/well of the PBS solution. 
7. Incubation with the primary rabbit anti-luciferase antibody (Abcam, 1:1000) at 37°C 
for one hour. 
8. The cells were washed 3 times with 750 µl/well of the PBS solution. 
9. Incubation with the secondary goat anti-rabbit Cy-5 labeled antibody (Chemicon 
1:500) at 37°C for one hour. 
10. The cells were washed 3 times with 750 µl/well o f the PBS solution. 
 
The labeled cells were visualized under inverted fluorescent microscope Axiovert35 (Zeiss).  
3.3.5 SDS-PAGE 
 
The sodium dodecyl sulfate (SDS) – polyacrylamid gel electrophoresis (PAGE) was 
performed in tricine gel (Schaegger and Jagow, 1987), cast in chambers with dimensions of 
8.5 x 6 cm. The electrophoresis was run in an electrophoresis chamber manufactured in the 
working factory of the MZI Giessen. Solution of 12% acryl amide in gel buffer was used for 
preparing the resolving gel. The used acryl amide (AppliChem, Darmstadt) was a 40 % 
solution mixture of acryl amide and N, N’-methylen-bis-acrylamide in 29:1 ratio. 
Polymerization of the resolving gel was initialized by adding 0.05% (w/v) Ammonium 
persulfate (APS) and 0.1 % (v/v) TEMED. The stacking gel was prepared as a 4% acryl 
amide solution in gel buffer, polymerized by addition of 0.08% (w/v) ammonium persulfate 
(APS) and 0.1 % (v/v) TEMED. The probes (cells and supernatant) were lysed in SDS lysis 
buffer supplied with 5% (v/v) ß-mercaptoethanol and incubated at 94°C for 10 minutes to 
achieve complete protein denaturation. The probes were run at 120 V for 90 min., together 
with a pre-stained molecular marker (Pre-stained Protein Marker Broad Range, NEB). 
Following electrophoresis, the gel was removed and the stacking gel was removed. The 
remaining resolving gel was consequently processed for Western blot.  
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3.3.6 Western blot  
 
The transfer of the electrophoretically separated proteins (3.3.5) to the nitro-cellulose 
membrane Bio Trace NT (Pall Gelman Laboratory) was carried out in electric field using the 
“semi-dry” blotting technique. For this purpose the Trans-Blot® SD (BioRad) electro blotting 
system was used, as recommended by the manufacturer. The gel was soaked into the cathode 
buffer for 5 minutes, whereas the membrane in the anode buffer. Additionally, 6 filter papers 
(Whatman) with the size of the gel were soaked into the appropriate transfer buffers: 3 of 
them into the anode, and the other 3 into the cathode buffer. The three filter papers soaked 
into the anode buffer were layed directly on the anode plate, followed by the membrane and 
the gel. The other 3 filter papers soaked into the cathode buffer were placed on the top of the 
gel. This stacked formation was gently pressed with a glass pippet in order to remove the air 
from between the layers. Finally, the cathode was placed over the cathode-soaked filter papers 
and electrical current was applied (5mA/cm2 and maximally 13 V) for 30 min. Following the 
protein transfer, the membrane was incubated in a 5% (w/v) low-fat milk solution in PBS-
Tween (0.05% (v/v) Tween-20 in PBS) at room temperature for at least 1 hour, in order to 
block the free binding sites of the membrane. In addition, the membrane was incubated at 4°C 
overnight in order to reduce the non-specific binding of the antibodies even more. On the next 
day the membrane was rinsed with PBS-Tween and incubated with the polyclonal goat anti-
canine IL-12 antibody (R&D Systems) at concentration of 0.15µg/ml (diluted in PBS/Tween) 
for 1 hour. Afterwards the membrane was washed for 10 minutes three times in PBS/Tween, 
followed by incubation with 0.5 mg/ml of the second rabbit anti-goat (H+L) alkaline 
phosphatase AP-conjugated antibody (Novus Biologicals) at room temperature for 1 hour. 
The membrane was washed three times with PBS/Tween for 10 min. Following the last 
washing step, the membrane was incubated in 15 ml of a pre-mixed substrate solution 
BCIP/NBT (Sigma). After the development of a visible reaction in form of a colored line, the 
reaction was stopped by adding ddH2O to the substarte solution. The membrane was 
documented and stored at 4°C. 
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3.4 Detection of rcscIL-12 bioactivity  
 
3.4.1 PBMC Isolation 
 
The density gradient centrifugation was used for PBMC isolation according to a protocol 
previously established in our lab and adapted for canine PBMC (GONDOLF, 1994; 
GONDOLF et al., 1996). Male, healthy, vaccinated and routinely dehelmintized Beagle dogs 
between 1.5 - 4 years of age (routine blood donors from the small animal clinic, department of 
internal medicine and from the clinic of obstetrics, gynecology and andrology) were used as 
blood donors. The blood was sampled in the morning by venupuncture of the jugular vein 
under standard sterile conditions. After sampling, the heparanized blood was diluted at ratio 
of 1:3 with sterile RPMI (PAA) medium supplied with 1% peniciline/streptomycine (PAA) 
and  without fetal calf serum. Five milliliters of the diluted blood were layed on top of 3 ml of 
the 58.5% Percoll (Amersham) medium in conical glass tubes. The layered blood was 
centrifuged at 800 x g for 25 minutes without using the brake. The resulting band (fig. 23, 
attachment) was removed by a pasteur pipette and lymphocyte bands from 3-4 glass tubes 
were pooled together in a new conical tube containing 5ml RPMI (1% 
peniciline/streptomycine) culture medium supplied with 10 % fetal calf serum. The pooled 
lymphocytes were pelleted by centrifugation at 400 x g for 5 min. using the brake, the 
supernatant was discarded and the pellets from 3 tubes were pooled again by resuspension in 
2 ml RPMI complete medium. Such pooled lymphocytes were centrifuged and another three 
pellets were pooled together until only one tube left. This was resuspended in 3 ml complete 
medium and the cell number and viability was determined by Trypan blue exclusion assay. 
 
3.4.2 PBMC pre-stimulation 
 
The isolated PBMCs were always incubated at concentration of 5 x 106/ml. Depending on the 
experiment they were treated with 100 U/ml of the rhIL-2 (PeproTech) for different intervals 
(5 or 7 days). In each case after the initial three days of incubation the cells were re-supplied 
with the same amount of medium and rhIL-2 (100 U/ml).  
 
 28  3   Materials and Methods
 
 
3.4.3 IFN-γ ELISA 
 
Canine IFN-γ Quantikine®, a sandwich ELISA based kit (R&D Systems) was used to quantify 
the amounts of canine IFN-γ produced by the canine PBMCs. The IFN-γ was determined in 
the supernatants of cultured lymphocytes. For this purpose, suspensions of the cultured cells 
were transferred into 1.5 ml conical tubes which were centrifuged in a microcentrifuge at full 
speed (14.000 rpm) for 2 minutes, in order to pellet the cells and the small amount of debris 
present in the suspension. After obtaining a cell-free supernatant, the protocol was performed 
according to the manufacturer’s recommendations: 
 
1. 50 µl of each probe, 50 µl PBS (negative control) or 50 µl of the standard IFN-γ 
solution (positive control) were transferred into wells of the ELISA plate pre-coated 
with mouse monoclonal anti canine IFN-γ antibody and incubated for 2 hours.  
2. Afterwards the wells were washed 3 times with 300 µl /well of the washing buffer.  
3. 100 µl/well of the biotynilated monoclonal anti cIFN-γ antibody was added and the 
wells incubated for one hour. 
4. The biotynilated antibody was removed and the wells were washed 3 times with 300 
µl/well of the washing buffer. 
5. 100 µl/well of a streptavidine-attached horse reddish peroxidase (HRP) was added to 
the samples and the wells were incubated for 30 min.  
6. The streptavidine-HRP was removed and the wells washed again 3 times with 300 
µl/well of the washing buffer 
7. 100 µl/well of a pre-mixed peroxidse substrate was added and incubated for 30 
minutes in dark.  
8. 100µl/well of the stop solution (1 M H2SO4) were added and the optical density was 
determined within the next 5 min. by a spectrophotometer (Titertek Multiscan Plus, 
Titertek) at 450 nm wavelength with 630 nm wavelength serving as a background 
correction.  
 
The raw O.D. values were then plotted on a graph and the approximate amount of cIFN-γ 
produced was determined from the standard curve which was obtained in each experiment 
with known concentrations of IFN-γ (0-4000 pg/ml). 
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3.4.4 BrdU ELISA 
 
The BrdU incorporation was used to investigate the proliferation of stimulated cells. For this 
purpose ELISA-based BrdU detection was applied (WAGNER et al., 1998, WAGNER, 1999) 
using the BrDU ELISA kit (Roche Diagnostics), according to the manufacturer’s 
recommendations. Shortly, triplicates of each probe were incubated in 100 µl volume in 96-
well multiplate for the given time with the appropriate stimuli and the appropriate controls. 
Then they were processed according to the following protocol: 
1. 10 µl of the BrdU labeling solution were added per well.  
2. The cells were incubated at 37°C for 16 h. 
3. The lymphocyte suspensions were thoroughly mixed by pippeting up and down in 
order to disrupt eventual cell agglutinates. 
4. The 96-well plate was centrifuged at 400 x g for 10 min.  
5. The supernatant was removed by flicking off. 
6. The cells were dried with a hair dryer for 10 min. 
7. 200 µl of ethanol based fixation/permeabilisation solution was added per well and 
the plate was incubated for 30 min. 
8. The fixative was removed by flicking off, and the plate was left to drain on a clean 
paper. 
9. 100 µl of the peroxidase labeled anti-BrdU antibody working solution was added 
to each well and the plate was incubated for 90 min. 
10. The antibody solution was removed by flicking off, and the wells were washed 
three times with 300 µl/well of the washing solution. 
11. After removing the washing buffer a ready-to-use substrate solution was added to 
the wells, and they were incubated until a blue color developed. 
12. 25 µl of 1 M H2SO4 were added to stop the substrate solution and afterwards the 
optical density of the wells was determined at 450 nm in less then 5 minutes. The 
wavelength of 630 nm served as a correction. 
 
For evaluating the results of the BrdU ELISA the mean was calculated from the triplicates 
and the results were displayed as raw values of the optical density. 
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3.4.5 Cytotoxicity assay (Rose Bengal Assay) 
 
For determining the cytotoxic activity of canine PBMC, a method established in our lab 
(GONDOLF, 1994; GONDOLF et al., 1996) was used. Two routinely utilized cell lines, 
namely CTAC as a NK-sensitive and VERO as a NK-non-sensitive cell line were used as 
target cells for the cytotoxic activity of the PBMC. According to the optimal conditions 
determined by GONDOLF et al. (1996), 1x104 target cells were plated in a 96-well plate and 
incubated for 26 hours in order to achieve optimal monolayers. After this incubation time, 
effector PBMC were added in different effector to target (E:T) ratios (varying from 100: 1 to 
25:1) and incubated at 37°C (5% CO2) for additional 14 h. Following this incubation period 
the effector cells and the killed, no longer adherent target cells were removed using a 
multichannel pipet. Subsequently, 100 µl of 0,25% Rose Bengal (Sigma) working solution 
was added to stain the remaining, still adherent target cells for 3 min. The Rose Bengal color 
was removed from the supernatant by flicking off and the cells were washed three times with 
300 µl/well of the PBS-NaCl washing solution (pH 7.4) to completely remove the 
extracellular color. The remaining target cells, which had absorbed the dye were lysed with 
200 µl/well of ethanol-PBS (50:50 v/v) solution and incubated for 5 min. in order to allow 
releasing of the dye from the cells. The optical density of the resulting solution was 
determined in a spectrophotometer at 570 nm wavelength, with the wavelength of 630 nm 
serving as a background correction. The O.D. values of target cells incubated without effector 
cells were considered as 100 % and the cytotoxicity of the effector cells was determined using 
the following formula:  
 
 
Cytotoxic activity    =    100  –                                     x  100 
 
 
It should be mentioned that negative values can result using this formula in some of the 
effector-target suspensions (sample) were effector cells did not exhibit cytotoxic activity. 
However, despite the lack of cytotoxic activity, adherence of effector to target cells occurred  
 
 
O.D. of the sample                                      
O.D. of the control 
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leading to higher absorbance (higher O.D. values) in these wells than in the control wells 
(target cells only). These negative values were considered as zero cytotoxicity. 
 32  4   Results
  
 
4 RESULTS 
 
4.1 Construction of the rcscIL-12 
 
4.1.1 Repair of the cDNA coding for the IL-12 p35 sequence 
 
The cDNA coding for the IL-12 p35 sequence was completed as described (s. 3.2.1). The 
amplicon of the first six exons is presented in fig. 2 as amplified with the respective primers. 
All three bands represent amplicons of the same sequence amplified using different annealing 
temperatures by gradient PCR. All products exhibited the expected length of 514 bp and 
correct amplification was afterwards confirmed by sequencing (MWG Biotech, Germany).  
Fig. 3 shows the amplicon obtained by amplification of exon 7 from genomic DNA using the 
appropriate primers (3.2.1). After isolating and cloning of this amplicon, its sequence was 
confirmed by sequencing (MWG Biotech, Germany). 
 
                                                        
 
 
 
 
The amplicons of the sequences for exons 1-6 and for exon 7 were processed as described 
(3.2.1). Fig. 4 shows the amplicons of the ligation product of exon 1-6 with exon 7 using the 
corresponding primers (3.2.1). All bands represent the same amplicons obtained at different  
 
Fig 2: Amplicons (gradient PCR) of 
the sequence of exons1-6 of the p35 
subunit; all three bands show the 
same length of 500 bp 
Fig 3: Amplicon of the sequence of  
exon7 of the p35 subunit (right lane),  
with length of 170 bp 
500 bp 
200 bp 
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annealing temperatures using gradient PCR. The resulting complete sequence of the p35 
subunit was confirmed by sequencing at MWG. 
                                       
                                                       
 
 
4.1.2 Correction of the cDNA coding for the IL-12 p40 
 
The result of the corrections of the mismatched bases is the sequence presented in fig. 5. After 
the last site-directed mutagenesis had been performed, the resulting plasmid was isolated and 
sent for sequencing (MWG Biotech, Germany). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4: Amplicons of the complete sequence of the 
p35 subunit ; all 5 lanes show the same lenght of 
669 bp 
 
  1   atgcatcctcagcagttggtcatctcctggttttccctcgttttgctggcgtcacccctc 60                                                                  
   61  atgaccatatgggaactggagaaagatgtttatgttgtagagttggactggcaccctgat 120                                                                      
   121 gcccccggagaaatggtggtcctcacctgccatacccctgaagaagatgacatcacttgg 180 
   181 acctcagcgcagagcagtgaagtcctaggttctggtaaaactctgaccatccaagtcaaa 240 
   241 gaatttggagatgctggccagtatacctgccataaaggaggcaaggttctgagccgctca 300 
   301 ctcctgttgattcacaaaaaagaagatggaatttggtccactgatatcttaaaggaacag 360 
   361 aaagaatccaaaaataagatctttctgaaatgtgaggcaaagaattattctggacgttt 420 
   421 cacatgctggtggctgacggcaatcagtactgatttgaaattcagtgtcaaaagtagcag 480 
   481 aggcttctctgacccccaaggggtgacatgtggagcagtgacactttcagcagagagggt 540 
   541 cagagtggacaacagggattataagaagtacacagtggagtgtcaggagggcagtgcctg 600 
   601 cccctctgccgaggagagcctacccatcgaggtcgtggtggatgctattcacaagctcaa 660 
   661 gtatgaaaactacaccagcagcttcttcatcagagacatcatcaaaccagacccacccac 720 
   721 aaacctgcagctgaagccattgaaaaattctcggcacgtggaggtcagctgggaataccc 780 
   781 cgacacctggagcaccccacattcctacttctccctgacattttgcGtacaggcccaggg 840 
   841 caagaacaatagagaaaagaaagatagactctgcgtggacaagacctcagccaaggtcgt 900 
   901 gtgccacaaggatgccaagatccgcgtgcaagcccgagaccgctactatagttcatcctg 960 
   961 gagcgactgggcatctgtgtcctgcagttaggttccacccccaggatgaatcttgg 1016 
 
Fig 5: IL-12 p40 sequence after the mismatch corrections (indicated in red colour, 
capital letters) performed by site-directed mutagenesis  
600 bp 
 34  4   Results
  
 
4.1.3 Construction of the rcscIL-12 
The ligation product of the cDNAs coding for the p35 and p40 subunits was cloned and 
processed as described (3.2.3). Fig. 6 shows the amplification product of this constructed 
sequence with the expected length of 1.6 kb. 
 
                                               
          Fig 6: Amplicon of the sccIL-12  
          sequence (right lane) 
 
4.1.4 Construction of the rcscIL-12/Luciferase/pTRUE vector  
 
The successful construction of the rcscIL-12 enabled the completion of the plasmid required 
for expression of functional canine IL-12. Fig. 7 shows the amplicons of all sequences 
required to construct this plasmid: the rcscIL-12 (band 1, 1.6 kb), the IRES/Luciferase 
cassette (band 2, 2.5 kb) and the pTURE vector (band 3, 3 kb). Following the cloning of this 
vector construct, restriction digestion was used as a first confirmation of the successful 
cloning. Fig. 8a shows the restriction fragments obtained after digestion with the following 
restriction enzymes: Avr II (lane 2), and Mlu I and Sph I (lane 3). Lane 1 shows the 
undigested plasmid with total length of 7.1 kb. A closer view of the restriction sites is 
presented in fig.8b. Thus, the blue lines represent the restriction sites for the Avr II, 
positioned at base pair 90 of the IRES/Luciferase cassette and at base pair 214 of the rcscIL-
12 sequence. The resulting restriction fragments are 1.5 and 5.6 kb in length. Restriction 
digestion with Mlu I and Sph I, which cut at base pair 1 and base pair 1200 of the 
IRES/luciferase cassette, respectively, produces restriction fragments of 1.2 and 5.9 kb. 
 
 
1500 bp 
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     1    2     3 
Fig 7: PCR control of the 
sequences to be ligated: Lane1: 
rcscIL-12; lane 2: IRES/luciferase 
cassette; lane 3: pTRUE vector 
Figure 8a: Restriction digestion control 
after the ligation of the rcscIL12 and 
IRES/luciferase into pTRUE vector. 
Lane 1:undigested plasmid; lane 2: 
restriction fragments of the digestion 
with the AvrII; lane 3:restriction 
fragments of the digestion with the MluI 
and SphI  
           1      2      3    
Fig 8b: The pTRUE↔rcscIL-12↔IRES/Luciferase 
plasmid. Dotted line: rcscIL-12 (1.6 kb); spotted line: 
IRES/Luciferase cassette (2.5 kb); filled line: pTURE 
plasmid (3 kb). Blue lines: restriction sites for the AvrII; 
red line: restriction site for the MluI; green line: 
restriction site for the the Sph I. 
 
1500 bp 
1500 bp 
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4.2 Establishing of rcscIL-12 containing BHK Tet-On cell line 
 
4.2.1 Transfection of the BHK Tet-On cell line 
 
Following successful cloning of the pTRUE vector with the cDNAs encoding rscsIL-12 and 
luciferase, the construct was stably transfected into the BHK Tet-On cell line. Transfected 
cells surviving the neomycine /puromycine selection pressure were selected as described 
(3.3.2). As demonstrated in the luciferase assay (fig. 9, table 1), only four from ten 
populations surviving the selection process reached confluence in a 10 cm Petri dish. Cells 
from these populations were incubated with Doxycycline overnight, and the luciferase activity 
was analyzed. The following values of absolute light units were recorded after the 
luminescence measurement: population 2 (6393.9), population 3 (16.315), population 5 
(45618) and population 6 (44503). Aliquots of the same cell populations incubated without 
Doxycycline showed much more lower values of the absolute light units: population 2 
(128.36); population 3 (4.682); population 5 (724.33) and population 6 (634.17). According to 
these values the induction index was calculated for each population as described (3.3.3), 
giving the following values: population 2 (49.8), population 3 (3.48), population 5 (62.97) and 
population 6 (70.17). 
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      Fig 9:Luciferase assay values of the four populations from the initial cloning. Dotted  
       columns: cells incubated with doxycycline; closed columns: cells incubated  
       without Doxycycline  
 
According to these criteria, the highest values of the luciferase activity were shown by 
populations 5 and 6. Additionally, these populations showed the best induction index, 62.9 
and 70.1, respectively. In order to ensure the clonal nature of the future cell lines, cells of 
populations 5 and 6 were cloned using limited dilution cloning, as described (3.3.2). 
Following cloning, five clones from each population were grown to confluence in a 10 cm 
Petri dish and were tested on luciferase activity.  
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The results of the first subcloning procedure are presented in fig. 10. According to the 
luciferase assay values, the induction index (in brackets) was as follows: clone 5.1 (72.5) 
clone 5.2 (45.1), clone 5.3 (82.4), clone 5.5 (66.9), clone 6.1 (20.9), clone 6.2 (125.2), clone 
6.3 (106), clone 6.5 (64.08). Due to the highest induction index, the clones 6.2 and 6.3 were 
subcloned a second time. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
      Fig 10: Luciferase assay values of the first subcloning. Dotted columns: cells            
        incubated with doxycycline; closed columns: cells incubated without       
        Doxycycline 
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The values of the luciferase assay of the second subcloning procedure are presented in fig. 11. 
The values of the induction index of the respective clones are: clone 6.2.1 (102), clone 6.2.2 
(216), clone 6.2.3 (54), clone 6.2.4 (154), clone 6.2.5 (128), clone 6.3.1 (137), clone 6.3.2 
(184), clone 6.3.3 (177), clone 6.3.4 (143), clone 6.3.5 (221). On the basis of these data, the 
clones 6.2.2 and 6.3.5 were finally chosen as established cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
.         
 
 
 
 
 
 
 
 
 
 
      Fig 11: Luciferase assay values of the second subcloning. Dotted columns: cells         
                    incubated with doxycycline; closed columns: cells incubated without 
                    Doxycycline 
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A successful single-cell cloning assumes the presence of the transfected plasmid in every cell. 
Since the nature of the luciferase assay does not discriminate whether every cell contains the 
transfected plasmid, immunofluorescent staining of the transfected cells was additionally 
performed as described (3.3.4). As can be seen in figures 12a (clone 6.2.2) and 12b (clone 
6.3.5), both clones showed 100 % of positive cells, indicating that every cell contained the 
rcscIL-12 expressing plasmid. 
 
    a)               b)    
          Fig 12: Demonstration of bright orange-red fluorescence of the antibody- 
          labeled luciferase protein in the cytoplasm of all cells: a) clone 6.2.2; b) clone 6.3.5  
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4.2.2 Detection of the rcscIL-12 in the established cell line 
 
4.2.2.1 Detection of the rcscIL-12 protein 
 
Using Western blot analysis, the presence of the rscsIL-12 protein was confirmed in cell 
lysates as well as in the supernatant of the cell lines. Fig. 13 shows the Western blot 
performed with the lysate and the supernatant of the cell clone 6.2.2.  
     
                                         
    
 
 
 
 
 
The red band in the molecular weight marker (lane 1) resembles molecular weight of 72 kDa, 
indicating that the protein detected with a specific goat anti-cIL-12 polyclonal antibody on the 
membrane (lanes 3 and 5) is of similar molecular weight. In contrast, in the supernatant of 
non-induced cells (lane 2) as well as in lysates of non-induced cells (lane 4) we could not 
detect the protein of interest. 
 
 
 
 
 
       1        2          3         4        5 
72 kDa 
Fig 13: NBT/BCIP-based detection of the rcscIL-12 protein (~70 kDa) by Western 
blot analysis. Lane 1: marker; Lane 2: supernatant of Doxycycline non-induced 
cells; Lane 3: supernatant of Doxycycline induced cells; Lane 4: lysate of 
Doxycycline non-induced cells; Lane 5: lysate of Doxycycline induced cells. 
The positive reacting bands are indicated by brown color 
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4.2.3 Confirmation of bioactivity of the rcscIL-12 
 
Initially we investigated which assay is the optimal assay for investigating IL-12 bioactivity. 
In our experiments IFN-γ production by IL-2 induced canine lymphoblasts (in the following 
text called IL-2 lymphoblasts) proved to be the assay of choice over proliferation and 
cytotoxicity assays. Recombinant canine IL-12 (rcIL-12) (R&D Systems) was used as a 
standard in these establishing experiments. 
 
  
cIFN-gamma ELISA  
0
0,5
1
1,5
2
2,5
rcIL-12 negative ctrl.
IF
N
-
ga
m
m
a
 
(n
g/
m
l) 
 
55
5
       
cIFN-gamma ELISA 
0
0,5
1
1,5
2
rcIL-12 negative ctrl.
IF
N
-
ga
m
m
a
 
(n
g/
m
l) 
 
 
33
3
              
 
 
 
 
 
Thus, following incubation of IL-2 lymphoblasts with rcIL-12 for 48 h (fig.14) or 72 h 
(fig.15), a clear increase in the IFN-γ production was observed. Thus, IL-2 induced canine 
lymphoblasts incubated with medium only produced 0.08 and 0.05 ng/ml IFN-γ, whereas IL-2 
lymphoblasts incubated with recombinant canine IL-12 (R&D Systems) produced 2.3 and 
1.75 ng/ml IFN-γ after 48 and 72 hours, respectively. 
 
 
Fig 14: IFN-γ concentration in supernatants 
of canine IL-2 lymphoblasts after 48 h 
incubation. Dotted column: incubated with 
IL-12; closed column: incubated with 
medium only. 
Fig 15: IFN-γ concentration in supernatants  
of canine IL-2 lymphoblasts after 72 h  
incubation. Dotted column: incubated with 
IL-12 ; closed column: incubated with 
medium only. 
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As a next step the biological activity of the supernatant from the established BHK Tet-On cell 
line was analyzed. Fig.16 shows a representative experiment in which IFN-γ production by 
IL-2 lymphoblasts was measured after incubation with supernatant from clone 6.2.2. These 
experiments demonstrated that supernatants of both Doxycycline induced and Doxycyline 
non-induced cells of clone 6.2.2, stimulated IFN-γ production by the IL-2 lymphoblasts to the 
same extent. 
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Fig 16: IFN-γ concentration in supernatants of canine IL-2 
lymphoblasts incubated with the supernatants of cells of clone 
6.2.2; Dotted column: supernatant from Doxycycline induced 
cells; slashed column: supernatant from Doxycycline non-
induced cells; closed column: medium only.  
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In order to verify that the secretion of IFN-γ was due to the presence of rcscIL-12 in the 
supernatant of the transfected cell line (clone 6.2.2) a neutralization assay was performed. 
Therefore, a neutralizing anti-canine IL-12 antibody was incubated with the supernatant of 
clone 6.2.2 before adding it to the IL-2 pre-stimulated lymphoblasts, and IFN-γ production 
was measured. Fig. 17 shows the results of three representative neutralization experiments.  
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IL-2 lymphoblasts incubated with the rcIL-12 as positive control, produced 8.76 fold more 
IFN-γ than IL-2 lymphoblasts incubated with medium only (negative control). Similar 
amounts of IFN-γ (8.44 fold more than the negative control) were produced by IL-2 
lymphoblasts when incubated with the supernatant from clone 6.2.2. In contrast, IL-2 
lymphoblasts incubated with the clone 6.2.2 supernatant in presence of the neutralizing anti 
canine IL-12 antibody demonstrated only insignificant increase of IFN-γ compared to the 
negative control. 
 
Fig 17: Fold increase of IFN-γ concentration in supernatants of 
canine IL-2 lymphoblasts incubated for 24 h; open column: with 
rcIL-12 as a positive control; dotted column: with IL-12-
containing supernatant of the 6.2.2 cell line; slashed column: with 
IL-12 containing supernatant + anti-cIL-12 antibody. 
The mean value of the negative control (IL-2 lymphoblasts 
incubated with medium only) was taken as 1 
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4.3 Investigation of the biological effects of rcscIL-12 on canine PBMC  
 
4.3.1 Resting PBMC do not produce IFN-γ after stimulation with IL-12 
 
In order to determine the optimal conditions for IL-12 mediated stimulation of the anti-tumor 
activities in canine PBMC, we investigated if their pre-stimulation is needed, using IFN-γ 
production as read-out. Fig.18 demonstrates the IFN-γ production by freshly isolated resting 
PBMC after incubation with rcscIL-12 for 18 h. Freshly isolated PBMC did not produce 
significant amounts of IFN-γ in response to rcscIL-12 stimulation. In contrast, in the 
experiments presented previously (fig.14 – fig.17) showing significant increase in IFN-γ 
production, the canine PBMC were stimulated with IL-2 prior to the IL-12 addition. 
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Fig 18: O.D. of IFN-γ ELISA; resting PBMC incubated for 18 h; 
Dotted column: with rcIL-12; slashed column: with medium; 
closed column: blank; open column: IFN-γ standard. 
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4.3.2 IL-12 requires presence of IL-2 to induce IFN-γ production in IL-2 
lymphoblasts 
 
In the IL-12 stimulation experiments presented, IL-2 pre-stimulated lymphoblasts were 
centrifuged only once before adding the IL-12. This provided that small amounts of IL-2 were 
present during the incubation period with IL-12. However, upon complete removal of IL-2 
from the suspension (by three consecutive centrifugations), the IL-2 lymphoblasts did not 
produce detectable levels of IFN-γ following incubation with IL-12 (fig.19). 
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These experiments clearly show (fig. 18, fig. 19) that IL-12 alone is not sufficient to induce 
detectable levels of IFN-γ and that IL-2 pre-stimulation of canine lymphocytes is a 
prerequisite for efficient induction of IFN-γ by IL-12 in vitro.  
 
Fig 19: IFN-γ production upon IL-12 stimulation of IL-2 
lymphoblasts after complete removal of the IL-2 by three 
consecutive centrifugations; open column: standard IFN-γ; 
dotted column: IL-lymphoblasts stimulated with rcscIL-12 
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4.3.3 Proliferation of canine IL-2 lymphoblasts upon IL-12 stimulation 
 
After optimizing the conditions for IL-12 stimulation of canine PBMC, their proliferation was 
analyzed, using BrdU incorporation based ELISA. In contrast to commonly used protocols, 
we used IL-2 as a pre-stimulus instead of PHA-P. As described (3.4.2) cells were pre-
incubated with IL-2 and then stimulated with 50 µl of the supernatant of clone 6.2.2. The 
results of a representative experiment are presented in fig. 20, showing that there is not 
significant difference between IL-2 lymphoblasts incubated with and IL-2 lymphoblasts 
incubated without IL-12. In order to demonstrate that the cells were properly pre-activated 
with IL-2, a portion of the canine PBMC were pre-incubated with medium only instead with 
IL-2. These cells demonstrated significantly lower O.D. values than IL-2 lymphoblasts, 
indicating that IL-2 itself has indeed pre-stimulated the canine PBMC. 
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Fig 20: Cell proliferation measured by BrdU ELISA after 48 hours incubation of IL-
2 lymphoblasts. Empty column: with IL-2 + IL-12; dotted column: IL-2 only; 
slashed column: medium only. 
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4.3.4 Evaluation of the cytotoxic activity of canine IL-2 lymphoblasts upon 
stimulation with IL-12  
 
To investigate the anti-tumor effect of IL-12, the cytotoxic activity of IL-2 lymphoblasts upon 
IL-12 stimulation was determined using the RBA, as described (3.4.5). The results of these 
experiments are presented in fig. 21. Highly variable increases in the cytotoxic activity of IL-
12 stimulated IL-2 lymphoblasts compared to IL-2 lymphoblasts incubated without IL-12 
were observed. Thus, in only three from eight dogs, IL-12 stimulated IL-2 lymphoblasts 
showed increase in cytotoxic activity (dogs 1, 6 and 8) of more than 30 % than IL-2 
lymphoblasts incubated with medium only. IL-12-stimulated IL-2 lymphoblasts of three other 
dogs (dogs 2, 3 and 4), showed only a slight increase (less than 10%) in cytotoxic activity 
when compared to IL-2 lymphoblasts incubated with medium only. IL-12 stimulated IL-2 
lymphoblasts of two other dogs (dogs 5 and 7) revealed 20-30 % increase in their cytotoxic 
activity compared to that of IL-2 lymphoblasts alone.  
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Figure 21. Cellular cytotoxicity RBA Assay. IL-2 blasts incubated for 14 hours 
with the CTAC target cells. Spotted columns: in presence of rcscIL-12; slashed 
columns: in presence of medium only. 
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Taken together, it can be stated that the presence of IL-12 induced cytolytic activity in canine 
lymphoblasts, which was not even present in cells incubated without IL-12, or in the majority 
of lymphocyte preparations more or less significantly increased the cytolytic activity.  
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5 Discussion  
 
The goal of this project was (1) to provide a continuous source of canine IL-12 for use in 
tumor immunotherapy studies in dogs by establishing a stably transfected BHK Tet-On cell 
line, and (2) to investigate the biological activities of the recombinant IL-12 in order to find 
the optimal conditions for in vitro stimulation of the anti-tumoral activities of canine PBMC. 
For accomplishing the first goal the stably transfected cell line must demonstrate continuous 
IL-12 secretion over long time periods, ideally over several hundred passages. A stable and 
reliable IL-12 producing cell line is of great importance for the planned future studies of 
adoptive canine immunotherapy. Thus, the IL-12 producing cell line, together with another, 
IL-2 producing BHK Tet-On cell line previously established in our lab, can be used for 
stimulation of canine lymphocytes in a co-culture system (FALKENBERG et al., 1995; 
FALKENBERG, 1998). In this system, a bioreactor comprising of two compartments 
separated by a semi-permeable membrane with a cut off of 100 kDa, the IL-12 and IL-2 
producing cell lines will be able to stimulate the canine lymphocytes, thus providing in vitro 
conditions very similar to conditions found in vivo. With help of the semi-permeable 
membrane it will be provided that only IL-12 (70 kDa), IL-2 (35 kDa) and some smaller 
molecules pass the barrier between the compartments, ensuring that there is no direct contact 
between the lymphocytes and the BHK cell line(s). In this way by continuous secretion of 
cytokines optimally stimulated canine lymphocytes will be available for adoptive 
immunotherapy of tumor-bearing dogs. 
The main prerequisite for obtaining such a cell line is its clonal character. Our experimental 
data from the luciferase assay and especially from the immunofluorescent staining of the 
luciferase protein, certainly confirmed the clonal character of the established cell line. 
Additionally, the stability of the cell line was affirmed by Western blot, demonstrating the 
presence of IL-12 protein in the transfected BHK Tet-On cell lysate, as well as in the 
supernatant of cells of the 45-th passage. 
One important issue concerning the expression of biologically active IL-12, regardless if it 
would be used for in vitro stimulation or for an intra-tumoral delivery, is to avoid production 
of any other IL-12 form than the IL-12 p70 form. As mentioned (2.3), depending on the 
species and the source of IL-12, other forms of IL-12, such as IL-12 p40 monomers and  
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homodimers are produced the latter exhibiting antagonistic effects on the IL-12 p70 activity 
(HEINZEL et al., 1997).  
Since existence and function of these forms have not been investigated in dogs, their 
formation and biology are not predictable. In order to avoid any possible interference of these 
forms with the IL-12 p70, (HEINZEL et al., 1997) we chose to make a single-chain canine 
IL-12 construct. For this purpose, the cDNA sequences coding for p40 and p35 subunits were 
ligated together as described (3.2.3), resulting in IL-12 p70 monocystronic cDNA. This 
monocystronic cDNA assures transcription of both subunits from one promoter, avoiding the 
existence of separate mRNA transcripts of each of the subunits. Additionally, in order to 
ensure that the translated product of the monocystronic cDNA remains as an intact 
polypeptide chain during protein processing in the rough endoplasmic reticulum (ER), the 
leading sequence of the cDNA coding for the p35 subunit was omitted. Thus, we provide 
conditions which do not allow production of free p40 or p35 subunit by the transfected cell 
line. This was confirmed using western blot, demonstrating only one band of approximately 
70 kDa in the cell lysates and supernatants of the established cell line, which corresponds to 
the molecular weight of the IL-12 p70 heterodimer (KOBAYASHI et al., 1989). Since the 
anti-canine IL-12 antibody used detects p40 regardless in which form it is present, we 
conclude that the only form present in the established cell line is indeed the IL-12 p70 
heterodimeric form. 
For investigating the expression rate of the rccsIL-12 by the transfected cell line, the 
luciferase assay was used as an indirect indicator. Since the luciferase expression can be 
induced upon Doxycycline addition, inducibility and expression rate of the luciferase reporter 
gene were investigated. These experiments revealed more than 200-fold increase in luciferase 
activity of lysates of Doxycycline induced cells in comparison to lysates of Doxycycline non-
induced cells (s. 4.2.1., fig 11, table 3). The substrate excess in the luciferase assay provides 
conditions where one molecule of luciferase cleaves only one substrate molecule. This in turn 
means that one unit of luciferase activity is equal to one luciferase molecule. Due to the fact 
that luciferase and rcscIL-12 transcripts are located on monocystronic mRNA, the number of 
rcscIL-12 molecules is equal to the number of luciferase molecules. This linearity allows us to 
conclude that protein synthesis of rcscIL-12 increases by the same factor as the luciferase 
activity. These data are also important since only such approximate mode of quantification of 
IL-12 production was available, due to the lack of canine IL-12 ELISA at present time.  
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The second important point revealed by these experiments is the fact that supernatants from 
Doxycycline non-induced transfected BHK cells stimulated the same amount of IFN-γ by IL-
2 induced lymphoblasts (IL-2 lymphoblasts) as the supernatants from Doxycycline induced 
transfected BHK cells. This indicates that rcscIL-12 basal transcription also exists in absence 
of Doxycycline and is sufficient to stimulate the same amount of IFN-γ as supernatants from 
Doxycycline induced cells. Although the absolute IL-12 concentration could not be 
determined, our experimental data comply with the general observations made in IL-12 
studies in humans and mice. These observations demonstrate that IL-12 is a very potent 
cytokine being active in very low picomolar concentrations (CHAN et al., 1991).  
Finally, the neutralization assay performed with the neutralizing anti-canine IL-12 antibody 
confirmed that the IFN-γ production by canine IL-2 lymphoblasts upon incubation with the 
supernatant is due to the presence of rcscIL-12 alone. 
The second goal of this study was to determine the optimal conditions for IL-12 mediated 
anti-tumor effect of canine PBMC. Thus, the most important functions responsible for this 
effect such as IFN-γ production, lymphocyte proliferation, and the cytotoxic activity of canine 
PBMC toward tumor cell lines, were investigated in various experimental settings. 
Concerning IFN-γ production we found that resting canine PBMC do not produce detectable 
amounts of IFN-γ upon incubation with IL-12, whereas IL-2 induced lymphoblasts produce 
significant amounts of IFN-γ after IL-12 addition. The finding that resting canine PBMC do 
not produce IFN-γ after IL-12 stimulation is in contrast to studies who showed IFN-γ 
production by freshly isolated human lymphocytes after IL-12 stimulation (CHAN et al., 
1991). The same study also showed that IFN-γ can be equally induced in NK as well as in T 
cells. However, the reason for this difference between resting canine lymphocytes and canine 
lymphoblasts can only be hypothesized at current time. Moreover, a detailed analysis of the 
IFN-γ production by distinct canine lymphocytes is not feasible at this time due to lack of 
phenotypical characterization of canine NK cells. Nevertheless, since IFN-γ has important 
anti-tumor effects, finding the optimal conditions for its production by canine lymphocytes is 
an important issue. Thus, it would be important to determine which is the optimal IL-12 
concentration stimulating the highest amount of IFN-γ. Additionally, by investigating the 
kinetic of IFN-γ production in the course of time after IL-12 stimulation, the time interval of 
the highest and the most constant IFN-γ production can be determined. In this context our 
experiments only indicated that at 48 hours after IL-12 incubation canine IL-2 lymphoblasts  
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produced a significant amount of IFN-γ (2,3 ng/ml), whereas a slight decrease (1,8 ng/ml) can 
be observed after 72 hours. 
In contrast to other groups working with canine IL-12 who reported proliferation of canine 
PHA-P stimulated lymphoblasts (PHILLIPS et al., 1999), we did not find significant 
difference between IL-12 induced IL-2 lymphoblasts and IL-2 lymphoblasts incubated with 
medium only. However, the difference in the pre-stimulation protocol could be the 
explanation for this observed discrepancy. Thus, it is known from studies in human and mice 
that IL-2 preferentially induces proliferation of resting NK cells, whereas PHA-P stimulates 
the proliferation of CD3+
 
cells (ROBERTSON et al., 1992). Clarifying this question in dogs is 
not feasible at present due to the already mentioned lack of phenotypical characterization of 
canine NK cells. 
Finally, the cytotoxic function of canine IL-2 lymphoblasts upon incubation with rcscIL-12 
was investigated in 8 dogs. The results of these experiments revealed increased cytotoxic 
activity of canine IL-2 lymphoblasts upon incubation with rcscIL-12 for 16 hours, in all 
investigated animals. However, the increase was very variable between animals. Thus, in 
three of 8 dogs, IL-2 lymphoblasts alone did not demonstrate cytotoxic activity, whereas IL-
12 stimulated lymphoblasts showed between 35-75% cytotoxic activity (s. 4.3.4, fig 21, table 
11). In three other dogs the increase in cytotoxic activity of IL-12 stimulated IL-2 
lymphoblasts compared to IL-2 lymphoblasts without additional stimulation with IL-12 was 
between 20 and 30 %, whereas in two dogs this increase was less than 10% (s. 4.3.4, fig 21, 
table 11). These variations did not allow statistical analysis of the whole population 
investigated, although a tendency of increase in cytotoxic activity could be observed in IL-12 
stimulated IL-2 lymphoblasts. The redundancy in regulation of proteins responsible for 
cytotoxic activity, such as perforin and granzymes, could be one reason for these individual 
differences. Thus, the expression level of perforin in human is regulated by various different 
cytokines, such as IL-2, IL-4, IL-6, IL-7, IL-12 etc (YU et al., 1999). Additionally to the 
redundancy, genetic differences in regulatory sequences, for example polymorphism in 
perforin promoters, also play a role in the regulation of the cytotoxic proteins expression. 
Significant individual differences were also observed in a previous study from our lab (FUNK 
et al., 2003; FUNK et al., 2005) investigating the cytolytic potential of canine PBMC from 
tumor-bearing dogs. To sum up, our experimental data from the cytotoxicity assay give 
rationale for an approach where lymphocytes of each tumor-bearing dog would be screened in  
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vitro for their cytotoxic potential prior to submitting the patient to an adoptive 
immunotherapy.  
Additionally to the possibility of using the established cell line as a source for continuous 
lymphocyte stimulation with IL-12, the cDNA of the constructed rcscIL-12 could be used for 
gene delivery therapy in tumor patients. By introducing the IL-12 cDNA into the tumor, it 
would consequently secrete IL-12 and thus provide direct stimulation of tumor-infiltrating 
lymphocytes (BARAJAS et al., 2001; BRAMSON et al., 1996; FUJITA et al., 2007; 
GAMBOTTO et al., 1999). Some of the IL-12 gene delivery studies showed that the anti-
tumor activity of IL-12 is additive to classical anti-tumor therapies, like radiotherapy 
(FUJITA et al., 2007). Another advantage of gene delivery as a therapeutical approach is 
demonstrated by a recent study, which provides evidence that application of IL-12 directly 
into the tumor reverts the phenotype of tumor-associated macrophages from a pro-tumor into 
a pro-inflammatory phenotype (WATKINS et al., 2007). This reversal of macrophage 
phenotype is characterized by significant reduction in tumor growth and progression. The 
interest of gene delivery therapy has grown also due to the latest results from a study 
demonstrating that introduction of foreign DNA into tumor cells does not have to be 
performed exclusively with viral vectors (SHI et al., 2002). Moreover, according to the same 
study, transfection of naked (without using any carriers) plasmid into tumor cells results in 
protein production by the tumor.  
As a conclusion, recombinant canine single-chain IL-12 was constructed and its biological 
activities confirmed, making it a potential tool for further investigations in the area of 
immunology and especially tumor immunotherapy, as well for in vitro as for clinical 
investigations. 
As a protein source, the stably transfected cell line can be used in an appropriate bioreactor 
(FALKENBERG et al., 1995; FALKENBERG, 1998) where it would stimulate lymphocytes, 
which can be thereupon adoptively transferred into tumor patients. Furthermore, the 
nucleotide sequence could also be used for clinical studies exploring the effect of IL-12 
delivery directly into the tumor environment. 
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6 Summary 
 
1. In the course of this project a new source for canine IL-12 was established in the 
stably transformed BHK Tet-On cell line carrying the cDNA coding for the canine single-
chain interleukin-12 (IL-12). To create this construct, the cDNAs coding for the IL-12 
subunits p35 and p40 were ligated together, linked by a dekapeptide consisting of 2 bovine 
elastin motifs. The IL-12 cDNA and the cDNA encoding luciferase reporter gene were cloned 
into appropriate pTRUE Tet-On vector. The constructed plasmid was stably transfected into 
BHK Tet-On cell line, which offers the possibility for inducible expression of the IL-12 upon 
addition of Doxycycline to the cell culture medium. 
2. Using luciferase assays and immunofluorescent detection with polyclonal goat anti-
firefly luciferase of the reporter gene in the transfected cell clones, two cell lines were 
selected as stably transfected for further propagation. These cell lines demonstrated an 
induction index of more than 200 each and both showed 100 % of positive cells after 
immunofluorescent labeling of the luciferase protein. 
3. With help of IFN-γ ELISA, the biological activity of the transfected canine single-
chain IL-12 was confirmed in Doxycycline induced as well as in Doxycycline non-induced 
cells. Furthermore, the data from these experiments indicated a basal level of gene 
transcription from the inserted plasmid. Neutralization experiments with an anti-canine IL-12 
antibody demonstrated reversal of the increase in IFN-γ production by IL-2 lymphoblasts 
incubated with the supernatant of the constructed cell lines. Moreover, the supernatant and the 
cell lysate of induced cells were analyzed using western blot, demonstrating band of 
approximately 70 kDa, which is the expected molecular weight of the rcscIL-12. 
4. The levels of proliferation and cytotoxicity of canine PBMC, isolated by 
centrifugation of heparinized blood with a Percoll gradient, as well as their IFN-γ 
production were measured upon cscIL-12 stimulation. The data from these experiments 
indicated that IL-12 stimulates IFN-γ production in canine IL-2 lymphoblasts but not in 
resting canine PBMC. In addition, IL-2 lymphoblasts showed a very small but non-significant 
increase in proliferation upon IL-12 incubation, whereas, the increase in cytotoxicity of IL-2 
induced lymphoblasts after incubation with IL-12 demonstrated individual variations ranging 
from 2 up to 75 %. 
 
 
  
56  6   Summary
 
 
5. As final conclusion, the established cell lines constitutively express biologically active 
recombinant canine single-chain IL-12. Thus, this cell line can be used as a source of IL-12 
for stimulation of immune effector cells, especially NK or CD8+ cytotoxic T cells. Such 
stimulated cells can be used as lymphokine activated killer (LAK) cells in an adoptive cancer 
immunotherapy. Due to the continuous and constant source of IL-12, stimulation of effector 
cells achieves stimulation conditions, which resemble more closely those found in vivo. 
Additionally, the cDNA coding for the single chain canine IL-12 can also be used for a gene 
delivery therapy in tumor patients. 
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7 Zusammenfassung 
 
1. In  dieser Studie wurde eine neue Möglichkeit zur Herstellung von kaninem 
Interleukin-12 (IL-12) mit einer BHK Tet-On Zellinie geschaffen, welche mit einer für das 
kanine Einzelketten IL-12 kodierenden cDNA stabil transfiziert wurde. Für die Konstruktion 
dieser cDNA wurden die beiden einzelnen, für die IL-12 Untereinheiten p35 und p40 
codierenden cDNAs ligiert, indem sie durch eine Nukleotid Sequenz verbunden wurden, 
welche für ein aus 2 bovinen Elastin- Motifs bestehendem Dekapeptid kodiert. Die so 
konstruierte cDNA wurde zusammen mit der für die Luciferase kodierenden cDNA in den 
pTRE Tet-On Vektor kloniert. Dieser Vektor wurde anschließend in die entsprechende BHK 
Tet-On Zelllinie transfiziert, welche nun die induzierbare IL-12 Produktion durch  Zugabe 
von Doxyclin zum Zellkulturmedium ermöglicht.  
2. Mit Hilfe des Luciferase Assays und der Immunfluoreszenz, durchgeführt mit einem 
polyklonalen Ziegen-anti-Luciferase Antikörper zum Nachweis des Reportergens in den 
transfizierten Zellklonen, wurden zwei Zelllinien als stabil transfizierte Zelllinien für die 
weiteren Untersuchungen ausgewählt. Jede dieser beiden Zelllinien wies einen 
Induktionsindex von über 200 sowie die Expression des Reporter-Gens in 100 % der Zellen 
auf. 
3. Durch den IFN-γ ELISA konnte die biologische Aktivität des in den Überständen 
enthaltenden rcscIL-12 nachgewiesen werden, was sowohl für die Doxycyclin-induzierten als 
auch für die nicht induzierten Zellen zutraf. Die gewonnenen Daten ließen nämlich erkennen, 
dass ein basaler Level der Gentranskription des eingebauten Plasmids vorhanden ist. 
Neutralisierungstests mit einem anti-kaninen IL12-Antikörper (R&D Systems) wiesen klar 
darauf hin, dass die erhöhte IFN-γ Produktion von zuvor mit IL-2 induzierten Lymphoblasten, 
welche mit den Überstanden der transfizierten Zellen zuvor inkubiert worden waren, 
spezifisch auf die Anwesenheit des rcscIL-12 in den Überständen zurückzuführen ist. Darüber 
hinaus ergab der mit den Überständen und auch mit den Zelllysaten der induzierten Zellen 
durchgeführte  Western Blot die erwartete Bande von annähernd 70 kDa.  
4. Das kanine single-chain IL-12 wurde bezüglich stimulierender Einflüsse auf kanine 
PBMC geprüft, die aus heparinisiertem Blut des Hundes zuvor über einer Percoll-Gradient 
isoliert worden waren. Dabei wurden die Proliferationsrate, die IFN-γ-Produktion und die 
zytotoxische Aktivität  der PBMC gemessen. Diese Ergebnisse zeigten, dass das rcscIL-12  
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nur bei den mit dem IL-2 vorstimulierten, nicht aber bei naiven PBMC die IFN-γ Produktion 
induzieren kann. Diese Ergebnisse zeigten weiterhin, dass die kaninen PBMC mit IL-2 
vorstimuliert werden müssen, um eine signifikante Erhöhung der IFN-γ Produktion durch 
rcscIL-12 zu induzieren, dass aber dann auch die anti-Tumorantwort der Effektorlymphozyten 
deutlich erhöht wird. Die mit IL-2 vorstimulierten Lymphoblasten zeigten allerdings nur eine 
sehr geringe und nicht signifikante Erhöhung ihrer Proliferationsrate nach der Inkubation mit 
IL-12, während ihre Steigerung der zytotoxischen Aktivität eine hohe individuelle Variation 
von 2 - 75% zwischen den einzelnen Hunden aufwies. 
5. Als Schlussfolgerung kann man feststellen, dass die konstruierten Zelllinien das 
biologisch aktive Einzelketten IL-12 dauerhaft exprimieren. Dem zu Folge können diese 
Zelllinien als eine definierte und etablierte Quelle von kaninem IL-12 zur in-vitro 
Stimulierung von Immuneffektorzellen, insbesondere der NK und der CD8+ zytotoxischen  T 
Zellen als Lymphokin-aktivierte Killer- (LAK) Zellen in einer adoptiven 
Tumorimmuntherapie verwendet werden. Auf Grund der kontinuierlichen Sekretion des IL-12 
kann eine dauerhaften Wirkung auf Effektorzellen in vitro erzielt werden, was den natürlichen 
Bedingungen in vivo ähnlich ist. Zusätzlich könnte die für die Einzelketten IL-12 kodierende 
cDNA-Sequenz bei Tumorpatienten für eine Gentherapie sogar als nackter Plasmidvektor 
eingesetzt werden. Neueste Experimente haben nämlich gezeigt, dass Virusvektoren nicht 
notwendiger Weise für eine effektive Gentherapie herangezogen werden müssen. 
 
 
 
 8   Bibliography  59 
 
 
8 Bibliography 
 
ABRAHAM, E.P., CHAIN, E. (1940): 
An enzyme from bacteria able to destroy penicillin. Nature 46: 837 
 
ANDERSON R, MACDONALD I, CORBETT T, HACKING G, LOWDELL MW, 
PRENTICE HG. (1997): 
Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): 
delivery to acute myeloid leukemic blasts using adeno-associated virus. Human Gene Ther. 8: 
1125-1135 
 
BARAJAS, M., MAZZOLINI, G., GENOVE, G., BILBAO, R., NARVAIZA, I., SCHMITZ, 
V., SANGRO, B., MELERO, I., QIAN, C., PRIETO, J. (2001): 
Gene Therapy of Orthotopic Hepatocellular Carcinoma in Rats Using Adenovirus Coding for 
Interleukin 12. Hepatology 33: 52-61. 
 
BONNEMA, J.D., RIVLIN, K.A., TING, A.T., SCHOON, R.A., ABRAHAM, R.T., 
LEIBSON, P.J. (1994):  
Cytokine-Enhanced Nk Cell-Mediated Cytotoxicity. Positive Modulatory Effects of Il-2 and Il-
12 on Stimulus-Dependent Granule Exocytosis. J Immunol 152: 2098-2104. 
 
BRAMSON, J., HITT, M., GALLICHAN, W.S., ROSENTHAL, K.L., GAULDIE, J., 
GRAHAM, F.L. (1996):  
Construction of a Double Recombinant Adenovirus Vector Expressing a Heterodimeric 
Cytokine: In Vitro and in Vivo Production of Biologically Active Interleukin-12. Hum Gene 
Ther 7: 333-342. 
 
BRAMSON, J.L., HITT, M., ADDISON, C.L., MULLER, W.J., GAULDIE, J., GRAHAM, 
F.L. (1996):  
Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression 
and Long-Lasting Immunity That Is Associated with Highly Localized Expression of 
Interleukin-12. Hum Gene Ther 7: 1995-2002. 
 
BRUNDA, M.J., LUISTRO, L., WARRIER, R.R., WRIGHT, R.B., HUBBARD, B.R., 
MURPHY, M., WOLF, S.F., GATELY, M.K. (1993): 
Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors. J Exp Med 
178: 1223-1230. 
 
BÜTTNER, M., BELKE-LOUIS, G., RZIHA, H.J., MCINNES, C., KAADEN, O.R. (1998): 
Detection, Cdna Cloning and Sequencing of Canine Interleukin 12. Cytokine 10: 241-248. 
 
CARRA, G., GEROSA, F., TRINCHIERI, G. (2000):  
Biosynthesis and Posttranslational Regulation of Human Il-12. J Immunol 164: 4752-4761. 
 
CHAN, S.H., KOBAYASHI, M., SANTOLI, D., PERUSSIA, B., TRINCHIERI, G. (1992): 
Mechanisms of Ifn-Gamma Induction by Natural Killer Cell Stimulatory Factor (Nksf/Il-12). 
Role of Transcription and Mrna Stability in the Synergistic Interaction between Nksf and Il-2. 
J Immunol 148: 92-98. 
 
  
60  8   Bibliography 
 
 
CHAN, S.H., PERUSSIA, B., GUPTA, J.W., KOBAYASHI, M., POSPISIL, M., YOUNG, 
H.A., WOLF, S.F., YOUNG, D., CLARK, S.C., TRINCHIERI, G. (1991): 
Induction of Interferon Gamma Production by Natural Killer Cell Stimulatory Factor: 
Characterization of the Responder Cells and Synergy with Other Inducers. J Exp Med 173: 
869-879. 
 
CHEHIMI, J., STARR, S.E., FRANK, I., RENGARAJU, M., JACKSON, S.J., LLANES, C., 
KOBAYASHI, M., PERUSSIA, B., YOUNG, D., NICKBARG, E., ET AL. (1992):  
Natural Killer (Nk) Cell Stimulatory Factor Increases the Cytotoxic Activity of Nk Cells from 
Both Healthy Donors and Human Immunodeficiency Virus-Infected Patients. J Exp Med 175: 
789-796. 
 
D'ANDREA, A., RENGARAJU, M., VALIANTE, N.M., CHEHIMI, J., KUBIN, M., ASTE, 
M., CHAN, S.H., KOBAYASHI, M., YOUNG, D., NICKBARG, E., ET AL. (1992): 
Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood 
Mononuclear Cells. J Exp Med 176: 1387-1398. 
 
DEBLAKER-HOHE, D.F., YAMAUCHI, A., YU, C.R., HORVATH-ARCIDIACONO, J.A., 
BLOOM, E.T. (1995):  
IL-12 Synergizes with Il-2 to Induce Lymphokine-Activated Cytotoxicity and Perforin and 
Granzyme Gene Expression in Fresh Human Nk Cells. Cell Immunol 165: 33-43. 
 
DUNN, G.P., OLD, L. J., SCHREIBER, R. D. 
The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360. 
 
EBERT, E.C. (2004):  
Interleukin-12 up-Regulates Perforin- and Fas-Mediated Lymphokine-Activated Killer 
Activity by Intestinal Intraepithelial Lymphocytes. Clin Exp Immunol 138: 259-265. 
 
FALKENBERG, F.W., WEICHERT, H., KRANE, M., BARTELS, I., PALME, M., 
NAGELS, H.O., FIEBIG, H. (1995): 
In vitro production of monoclonal antibodies in high concentration in a new and easy to 
handle modular minifermenter. J Immunol Methods 179: 13-29. 
 
FALKENBERG, F. W. (1998): 
Production of monoclonal antibodies in the miniPERM bioreactor: comparison with other 
hybridoma culture methods. Res Immunol 149:560-570 
 
FOSS, D.L., MOODY, M.D., MURPHY, K.P., JR., PAZMANY, C., ZILLIOX, M.J., 
MURTAUGH, M.P. (1999):  
In Vitro and in Vivo Bioactivity of Single-Chain Interleukin-12. Scand J Immunol 50: 596-
604. 
 
FUJITA, T., TIMME, T.L., TABATA, K., NARUISHI, K., KUSAKA, N., WATANABE, M., 
ABDELFATTAH, E., ZHU, J.X., REN, C., YANG, G., GOLTSOV, A., WANG, H., 
VLACHAKI, M.T., TEH, B.S., BUTLER, E.B., THOMPSON, T.C. (2007):  
Cooperative Effects of Adenoviral Vector-Mediated Interleukin 12 Gene Therapy with 
Radiotherapy in a Preclinical Model of Metastatic Prostate Cancer. Gene Ther 14: 227-236. 
 
 
 8   Bibliography  61 
 
 
FUNK, J. (2001) 
Quantitative Untersuchungen zur Zytotoxizität und Mitogenstimulation isolierter 
Blutleukozyten von Hunden mit unterschiedlichen Tumoren 
Vet Med Diss Gießen 
 
FUNK, J., SCHMITZ, G., BACH, U., FAILING, K., BURKHARDT, E. (2003):  
Influence of Different Tumour Types on Natural Cytotoxicity (Nk Cell Activity) and Mitogen-
Induced Lymphocyte Proliferation in Isolated Blood Lymphocytes from 110 Dogs with 
Tumours. Res Vet Sci 74: 129-135. 
 
FUNK, J., SCHMITZ, G., FAILING, K., BURKHARDT, E. (2005):  
Natural Killer (Nk) and Lymphokine-Activated Killer (Lak) Cell Functions from Healthy 
Dogs and 29 Dogs with a Variety of Spontaneous Neoplasms. Cancer Immunol Immunother 
54: 87-92. 
 
GAMBOTTO, A., TUTING, T., MCVEY, D.L., KOVESDI, I., TAHARA, H., LOTZE, M.T., 
ROBBINS, P.D. (1999):  
Induction of Antitumor Immunity by Direct Intratumoral Injection of a Recombinant 
Adenovirus Vector Expressing Interleukin-12. Cancer Gene Ther 6: 45-53. 
 
GATELY, M.K. (1993): 
Interleukin-12: A Recently Discovered Cytokine with Potential for Enhancing Cell-Mediated 
Immune Responses to Tumors. Cancer Invest 11: 500-506. 
 
GATELY, M.K., CARVAJAL, D.M., CONNAUGHTON, S.E., GILLESSEN, S., 
WARRIER, R.R., KOLINSKY, K.D., WILKINSON, V.L., DWYER, C.M., HIGGINS, G.F., 
JR., PODLASKI, F.J., FAHERTY, D.A., FAMILLETTI, P.C., STERN, A.S., PRESKY, D.H. 
(1996):  
Interleukin-12 Antagonist Activity of Mouse Interleukin-12 P40 Homodimer in Vitro and in 
Vivo. Ann N Y Acad Sci 795: 1-12. 
 
GATELY, M.K., DESAI, B.B., WOLITZKY, A.G., QUINN, P.M., DWYER, C.M., 
PODLASKI, F.J., FAMILLETTI, P.C., SINIGAGLIA, F., CHIZONNITE, R., GUBLER, U., 
ET AL. (1991):  
Regulation of Human Lymphocyte Proliferation by a Heterodimeric Cytokine, Il-12 
(Cytotoxic Lymphocyte Maturation Factor). J Immunol 147: 874-882. 
 
GERMANN, T., GATELY, M.K., SCHOENHAUT, D.S., LOHOFF, M., MATTNER, F., 
FISCHER, S., JIN, S.C., SCHMITT, E., RUDE, E. (1993):  
Interleukin-12/T Cell Stimulating Factor, a Cytokine with Multiple Effects on T Helper Type 1 
(Th1) but Not on Th2 Cells. Eur J Immunol 23: 1762-1770. 
 
GONDOLF, C. (1994) 
Untersuchungen zur Zytotoxizität von Natural Killer (NK)- und Lymphokin-aktivierten Killer 
(LAK)- Zellen aus dem peripheren Blut des Hundes. 
Vet Med Diss Gießen 
 
 
 
 
  
62  8   Bibliography 
 
 
GONDOLF, C., BURKHARDT, E., FAILING, K., STITZ, L. (1996):  
A New Colorimetric Method for Measuring Cell-Mediated Cytotoxicity in Dogs. Vet Immunol 
Immunopathol 55: 11-22. 
 
GOSSEN, M., BUJARD, H. (1992):  
Tight Control of Gene Expression in Mammalian Cells by Tetracycline-Responsive 
Promoters. Proc Natl Acad Sci U S A 89: 5547-5551. 
 
GOSSEN, M., FREUNDLIEB, S., BENDER, G., MULLER, G., HILLEN, W., BUJARD, H. 
(1995): 
Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766-1769 
 
GUBLER, U., CHUA, A.O., SCHOENHAUT, D.S., DWYER, C.M., MCCOMAS, W., 
MOTYKA, R., NABAVI, N., WOLITZKY, A.G., QUINN, P.M., FAMILLETTI, P.C., ET 
AL. (1991):  
Coexpression of Two Distinct Genes Is Required to Generate Secreted Bioactive Cytotoxic 
Lymphocyte Maturation Factor. Proc Natl Acad Sci U S A 88: 4143-4147. 
 
HASHIMOTO, W., OSAKI, T., OKAMURA, H., ROBBINS, P.D., KURIMOTO, M., 
NAGATA, S., LOTZE, M.T., TAHARA, H. (1999):  
Differential Antitumor Effects of Administration of Recombinant Il-18 or Recombinant Il-12 
Are Mediated Primarily by Fas-Fas Ligand- and Perforin-Induced Tumor Apoptosis, 
Respectively. J Immunol 163: 583-589. 
 
HEINZEL, F.P., HUJER, A.M., AHMED, F.N., RERKO, R.M. (1997):  
In Vivo Production and Function of Il-12 P40 Homodimers. J Immunol 158: 4381-4388. 
 
HODGE, D.L., MARTINEZ, A., JULIAS, J.G., TAYLOR, L.S., YOUNG, H.A. (2002): 
Regulation of Nuclear Gamma Interferon Gene Expression by Interleukin 12 (Il-12) and Il-2 
Represents a Novel Form of Posttranscriptional Control. Mol Cell Biol 22: 1742-1753. 
 
KOBAYASHI, M., FITZ, L., RYAN, M., HEWICK, R.M., CLARK, S.C., CHAN, S., 
LOUDON, R., SHERMAN, F., PERUSSIA, B., TRINCHIERI, G. (1989):  
Identification and Purification of Natural Killer Cell Stimulatory Factor (Nksf), a Cytokine 
with Multiple Biologic Effects on Human Lymphocytes. J Exp Med 170: 827-845. 
 
LING, P., GATELY, M.K., GUBLER, U., STERN, A.S., LIN, P., HOLLFELDER, K., SU, 
C., PAN, Y.C., HAKIMI, J. (1995):  
Human Il-12 P40 Homodimer Binds to the Il-12 Receptor but Does Not Mediate Biologic 
Activity. J Immunol 154: 116-127. 
 
MATTNER, F., FISCHER, S., GUCKES, S., JIN, S., KAULEN, H., SCHMITT, E., RUDE, 
E., GERMANN, T. (1993):  
The Interleukin-12 Subunit P40 Specifically Inhibits Effects of the Interleukin-12 
Heterodimer. Eur J Immunol 23: 2202-2208. 
 
MAZZOLINI, G., QIAN, C., XIE, X., SUN, Y., LASARTE, J.J., DROZDZIK, M., PRIETO, 
J. (1999):  
Regression of Colon Cancer and Induction of Antitumor Immunity by Intratumoral Injection 
of Adenovirus Expressing Interleukin-12. Cancer Gene Ther 6: 514-522. 
 8   Bibliography  63 
 
 
NASTALA, C.L., EDINGTON, H.D., MCKINNEY, T.G., TAHARA, H., NALESNIK, M.A., 
BRUNDA, M.J., GATELY, M.K., WOLF, S.F., SCHREIBER, R.D., STORKUS, W.J., ET 
AL. (1994):  
Recombinant Il-12 Administration Induces Tumor Regression in Association with Ifn-Gamma 
Production. J Immunol 153: 1697-1706. 
 
NASU, Y., BANGMA, C.H., HULL, G.W., LEE, H.M., HU, J., WANG, J., MCCURDY, 
M.A., SHIMURA, S., YANG, G., TIMME, T.L., THOMPSON, T.C. (1999):  
Adenovirus-Mediated Interleukin-12 Gene Therapy for Prostate Cancer: Suppression of 
Orthotopic Tumor Growth and Pre-Established Lung Metastases in an Orthotopic Model. 
Gene Ther 6: 338-349. 
 
NAUME, B., GATELY, M., ESPEVIK, T. (1992):  
A Comparative Study of Il-12 (Cytotoxic Lymphocyte Maturation Factor)-, Il-2-, and Il-7-
Induced Effects on Immunomagnetically Purified Cd56+ Nk Cells. J Immunol 148: 2429-
2436. 
 
NAUME, B., GATELY, M.K., DESAI, B.B., SUNDAN, A., ESPEVIK, T. (1993): 
Synergistic Effects of Interleukin 4 and Interleukin 12 on Nk Cell Proliferation. Cytokine 5: 
38-46. 
 
OKANO, F., SATOH, M., YAMADA, K. (1997):  
Cloning and Expression of the Cdna for Canine Interleukin-12. J Interferon Cytokine Res 17: 
713-718. 
 
PHILLIPS, B.S., PADILLA, M.L., DICKERSON, E.B., LINDSTROM, M.J., HELFAND, 
S.C. (1999):  
Immunostimulatory Effects of Human Recombinant Interleukin-12 on Peripheral Blood 
Mononuclear Cells from Normal Dogs. Vet Immunol Immunopathol 70: 189-201. 
 
PRESKY, D.H., YANG, H., MINETTI, L.J., CHUA, A.O., NABAVI, N., WU, C.Y., 
GATELY, M.K., GUBLER, U. (1996):  
A Functional Interleukin 12 Receptor Complex Is Composed of Two Beta-Type Cytokine 
Receptor Subunits. Proc Natl Acad Sci U S A 93: 14002-14007. 
 
RABINOWICH, H., HERBERMAN, R.B., WHITESIDE, T.L. (1993):  
Differential Effects of Il12 and Il2 on Expression and Function of Cellular Adhesion 
Molecules on Purified Human Natural Killer Cells. Cell Immunol 152: 481-498. 
 
RAKHMILEVICH, A.L., TURNER, J., FORD, M.J., MCCABE, D., SUN, W.H., SONDEL, 
P.M., GROTA, K., YANG, N.S. (1996):  
Gene Gun-Mediated Skin Transfection with Interleukin 12 Gene Results in Regression of 
Established Primary and Metastatic Murine Tumors. Proc Natl Acad Sci U S A 93: 6291-
6296. 
 
ROBERTSON, M.J., SOIFFER, R.J., WOLF, S.F., MANLEY, T.J., DONAHUE, C., 
YOUNG, D., HERRMANN, S.H., RITZ, J. (1992):  
Response of Human Natural Killer (Nk) Cells to Nk Cell Stimulatory Factor (Nksf): Cytolytic 
Activity and Proliferation of Nk Cells Are Differentially Regulated by Nksf. J Exp Med 175: 
779-788. 
  
64  8   Bibliography 
 
 
SAIKI, R.K., SCHARF S., FALOONA F., MULLIS K.B., HORN G.T., ERLICH H.A., 
ARNHEIM, N. (1985): 
Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for 
diagnosis of sickle cell anemia. Science 230: 1350-1354. 
 
SAMBROOK, J., RUSSEL,W.D. (2001) 
Molecular Cloning: A Laboratory Manual. NY: Cold Spring Harbor Laboratory Press 
 
SALDARRIAGA, O. A., PEREZ, L. E., TRAVI, B. L., MELBY, P. C. (2006): 
Selective enhancement of the type 1 cytokine response by expression of a canine interleukin 
(IL)-12 fused heterodimeric DNA. Vet Immunol Immunopathol 110: 377-388. 
 
SCHMITZ, G. (2000) 
Qualitative und quantitative Untersuchungen zur zytotoxischen Aktivität aus Hundeblut 
isolierter Leukozyten gegenüber verschiedenen kaninen Tumorzelllinien. 
Vet Med Diss Gießen 
 
SCHMITZ, G., ARMIEN, A.G., FONFARA, S., TEIFKE, J.P., BURKHARDT, E. (2003): 
Induction of Apoptosis by Canine Natural Killer Cells. J Vet Med A Physiol Pathol Clin Med 
50: 156-159. 
 
SHI, F., RAKHMILEVICH, A.L., HEISE, C.P., OSHIKAWA, K., SONDEL, P.M., YANG, 
N.S., MAHVI, D.M. (2002):  
Intratumoral Injection of Interleukin-12 Plasmid DNA, Either Naked or in Complex with 
Cationic Lipid, Results in Similar Tumor Regression in a Murine Model. Mol Cancer Ther 1: 
949-957. 
 
STRAUSS-AYALI, D., BANETH, G., SHOR, S., OKANO, F., JAFFE, C.L. (2005): 
Interleukin-12 Augments a Th1-Type Immune Response Manifested as Lymphocyte 
Proliferation and Interferon Gamma Production in Leishmania Infantum-Infected Dogs. Int J 
Parasitol 35: 63-73. 
 
THIERFELDER, W.E., VAN DEURSEN, J.M., YAMAMOTO, K., TRIPP, R.A., 
SARAWAR, S.R., CARSON, R.T., SANGSTER, M.Y., VIGNALI, D.A., DOHERTY, P.C., 
GROSVELD, G.C., IHLE, J.N. (1996):  
Requirement for Stat4 in Interleukin-12-Mediated Responses of Natural Killer and T Cells. 
Nature 382: 171-174. 
 
TRINCHIERI, G. (2003):  
Interleukin-12 and the Regulation of Innate Resistance and Adaptive Immunity. Nat Rev 
Immunol 3: 133-146. 
 
WAGNER, U. (1998): 
Ermittlung optimaler Parameter für die in vitro-Stimulation von Hundeblutlymphozyten mit 
Concanavalin A (ConA) und Phytohämagglutinin (PHA) zur Gewinnung von kaninem 
Interleukin (IL-2) aus Zellkulturüberständen. 
Vet Med Diss Gießen 
 
 
 
 8   Bibliography  65 
 
 
WAGNER, U., BURKHARDT, E., FAILING, K. (1999):  
Evaluation of Canine Lymphocyte Proliferation: Comparison of Three Different Colorimetric 
Methods with the 3h-Thymidine Incorporation Assay. Vet Immunol Immunopathol 70: 151-
159. 
 
WATKINS, S.K., EGILMEZ, N.K., SUTTLES, J., STOUT, R.D. (2007):  
Il-12 Rapidly Alters the Functional Profile of Tumor-Associated and Tumor-Infiltrating 
Macrophages in Vitro and in Vivo. J Immunol 178: 1357-1362. 
 
YIN, D.X., ZHU, L., SCHIMKE, R.T. (1996):  
Tetracycline-Controlled Gene Expression System Achieves High-Level and Quantitative 
Control of Gene Expression. Anal Biochem 235: 195-201. 
 
YU, C. R., ORTALDO, J. R., CURIEL, R. E., YOUNG, H. A., ANDERSON, S. K., 
GOSSELIN, P. (1999): 
Role of a STAT binding site in the regulation of the human perforin promoter. J Immunol 162: 
2785-90. 
 
ZITVOGEL, L., TAHARA, H., CAI, Q., STORKUS, W.J., MULLER, G., WOLF, S.F., 
GATELY, M., ROBBINS, P.D., LOTZE, M.T. (1994):  
Construction and Characterization of Retroviral Vectors Expressing Biologically Active 
Human Interleukin-12. Hum Gene Ther 5: 1493-1506. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 9   Attachment   I 
 
 
9 Attachment 
 
 
 
 
                                                       
    Fig 23: Percoll isolated PBMC (canine).  
    The white band of cells is located between the 
    clear upper column containing culture medium,  
blood plasma and platelets, and the lower column  
of packed red cells and polymorphonuclear leukocytes 
 
 
Originally measured values of the represented figures: 
 
 + Dox -  Dox 
Population 2 6393.9 128.36 
Population 3 16.315 4.682 
Population 5 45618 724.33 
Population 6 44503 634.17 
        Table 1. Raw values of the luciferase measurement of the initial screening procedure  
         (fig.9) 
 
 
 + Dox - Dox 
Clone 5.1 47172 650.58 
Clone 5.2 46889 1038.4 
Clone 5.3 46780 567.55 
Clone 5.5 46707 698.11 
Clone 6.1 46649 2224.6 
Clone 6.2 46480 371.27 
Clone 6.3 44161 416.56 
Clone 6.5 47023 733.78 
Table 2. Raw Luciferase values of the luciferase measurement of the first subcloning  
procedure (fig.10) 
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 + Dox - Dox 
Clone 6.2.1 46986 456.59 
Clone 6.2.2 46860 216.25 
Clone 6.2.3 46637 857.2 
Clone 6.2.4 46752 302.36 
Clone 6.2.5 46997 364.4 
Clone 6.3.1 38539 279.61 
Clone 6.3.2 29777 161.4 
Clone 6.3.3 44718 252.35 
Clone 6.3.4 43352 301.56 
Clone 6.3.5 45800 207.17 
Table 3. Raw Luciferase values of the luciferase measurement of the second subcloning  
procedure (fig.11) 
 
 
 rcIL-12 negative ctrl. 
Probe 1 2.3 0.146 
Probe 2 2.25 0.14 
        Table 4. Values of IFN-γ ELISA measurement in ng/ml (fig. 14) 
 
 
 rcIL-12 negative 
ctrl. 
IFN-
gamma 
(4ng/ml) 
IFN-
gamma 
(2ng/ml) 
IFN-
gamma 
(1ng/ml) 
Probe 1 0.876 0.088 1.57 0.812 0.522 
Probe 2 0.886 0.08    
        Table 4a. O.D. values of IFN-γ ELISA measurement (fig. 14) 
 
 
 rcIL-12 negative ctrl. 
Probe 1 1.8 0.045 
Probe 2 1.7 0.055 
        Table 5. Values of IFN-γ ELISA measurement in ng/ml (fig. 15) 
 
 
 rcIL-12 negative 
ctrl. 
IFN-
gamma 
(4ng/ml) 
IFN-
gamma 
(2ng/ml) 
IFN-
gamma 
(1ng/ml) 
Probe 1 1.276 0.089 2.332 1.478 0.787 
Probe 2 1.338 0.116    
        Table 5a. O.D. values of IFN-γ ELISA measurement (fig. 15) 
 
 
 IFN-γ (ng/ml) 
+ Dox 3.475 
- Dox 4 
negative ctrl. 0.55 
        Table 6. Values of IFN-γ ELISA measurement in ng/ml (fig. 16)
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 O.D. 
+ Dox 2.395 
- Dox 2.107 
negative ctrl. 0.507 
IFN-gamma (2ng/ml) 1.405 
Blank 0.032 
       Table 6a. O.D. values of IFN-γ ELISA measurement (fig. 16) 
 
 
Fold 
Increase 
positiv 
ctrl. 
supernatant supernatant 
+ anti-cIL-
12 
negative 
ctrl. 
Dog 1 5.1 4.9 0.6 0 
Dog 2 10.27 10.31 0.17 0 
Dog 3 11.1 10.17 0.08 0 
        Table 7. Fold increase of the IFN-γ production (fig.17) 
 
 
 positiv 
ctrl. 
supernatant supernatant 
+ anti-cIL-
12 
negative 
ctrl. 
Dog 1 3.005 2.95 0.83 0.5 
Dog 2 2.818 2.827 0.294 0.25 
Dog 3 0.558 0.514 0.05 0.046 
        Table 7a. O.D. values of IFN-γ ELISA measurement (fig. 17) 
 
 
standard IFN-gamma (2 
ng/ml) 
1,458 
+ rc IL-12 0,053 
medium 0,0475 
blank 0,0515 
        Table 8. O.D. values of IFN-γ ELISA measurement (fig. 18) 
 
 
 Dog 1 Dog 2 
Standard IFN-gamma (2ng/ml) 2 2 
+ cIL-12 0,12 0,06 
        Table 9. O.D. values of IFN-γ ELISA measurement (fig. 19) 
 
 
 IL-2 + IL-12 IL-2 medium 
Probe 1 0,58 0,56 0,124 
Probe 2 0,604 0,57 0,145 
        Table 10. O.D. values of BrdU ELISA measurement (fig. 20) 
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 IL-2 + IL-12 IL-2 
Dog 1 32,6 0 
Dog 2 97,3 95,29 
Dog 3 96,3 84,8 
Dog 4 45,7 42,5 
Dog 5 70,42 49,84 
Dog 6 62 0 
Dog 7 92,8 60,4 
Dog 8 72,8 0 
        Table 11. Percentage of cytotoxicity of the PBMC of eight investigated dogs (fig. 21) 
 
INSTRUMENTS AND DEVICES 
 
Consort pvba – Turnhout, Belgium 
 CONSORT E425, Electrophoresis power supply 
MJ Research Inc. - Waltham, MA USA 
 PTC-200 Peltier thermal cycler 
Schimadzu Corp. - Kyoto, Japan 
 UV-VIS 1202 Spectrophotometer 
Hereaus Holding - Hanau, Germany 
 Laborfuge 400R 
 Laminar air LB-48-C 
 Incubator 
Bachofer – Reutlingen, Germany 
 Bachofer UV-Lamp (254nm) 
Hettich Holding – Tuttlingen, Germany 
 Centrifuge ROTINA 48 RC 
Köttermann GmbH & Co KG - Uetze/Hänigsen, Germany 
 Waterbath  
Titertek – AL, USA 
 Microplate reader Titertek Multiscan Plus 
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REAGENTS AND MEDIA 
CELL CULTURE 
READY MEDIA AND KITS 
Alexis Corporation – Lausen, Switzerland   
 Puromycin dihydrochloride, ALX-380-028-M025 
Amersham Biosciences – Piscataway NJ, USA  
 Percoll® - density gradient medium  
Sigma Aldrich, St. Louis, MO, USA 
 Trizma® hydrochloride, T3253 
 Sodium dihydrogen phosphate, 20 mM, 82592 
 Sodium hydrogen carbonate, S5761 
PAA Laboratories, GmbH – Pashing, Austria 
 RPMI1640 cell culture medium E15-885 
 Fetal Bovine Serum Standard Quality, A15-101 
 Penicillin/Streptomycin 100x Concentrate, P11-010 
 Trypsin EDTA (1:250) 1x Concentrate, L11-004 
Merck, KAaG – Darmstadt, Germany 
 Potassium nitrate, 105065 
Roche – Penzberg, Germany 
 BrdU ELISA kit, 114444611001 
R&D Systems – Minneapolis, USA 
 Quantikine canine INF-γ ELISA, CAIF00 
 Goat anti-canine IL-12 polyclonal antibody, AF1969 
 Recombinant canine IL-12, 2118-CL 
Peprotech EC Ltd – London, Great Britain  
 Recombinant human IL-12, 200-02 
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SELF-MADE REAGENTS 
 
Rose Bengal Assay (RBA) 
NaCl-PBS, pH 7.4 
1.42 g Na2HPO4 x 2 H2O 
0.2 g KH2PO4 
8.0 g NaCl 
0.2 g KCl 
Ad 1000.0 ml Aqua dest., adjust the pH-value with 1 N HCl 
 
Rose Bengal stock solution 
0.25 g Rose Bengal 
Ad 100 ml NaCl-PBS 
Mix and keep at 4°C 
 
Ethanol-PBS 50% (v/v) 
Mix ethanol and NaCl-PBS in 1:1 ratio 
 
WORKING WITH NUCLEIC ACIDS 
 
ROTH – Karlsrue, Germany 
Ampiciline, K029.1 
Ethanol, 9065.1 
IPTG, CN08.2 
Isopropanol, 6752.1 
LB Agar, X969.2 
LB Medium, X968.2 
X-Gal, 2315.1 
 9   Attachment   VII 
 
 
 
 
Fermentas – Burlington, Canada 
Markers, SM1153, SM1163, SM1133 
6X loading dye, R0621 
MACHEREY-NAGEL GmbH &Co. KG – Düren, Germany 
NucleoSpin, 740615.250 
PEGLAB Biotechnologie, GmbH – Erlangen, Germany 
Taq Polymerase, 01-1000 
Novagen – Madison, WI, USA 
KOD HotStart Polymerase, 71086-3 
Qiagen – Hilden, Germany 
Superfect®, 301307 
A-addition kit, 231994 
 
WORKING WITH PROTEINS 
SDS PAGE 
 
Anode buffer 
200 mM Tris/HCl pH 8,9 
Gel buffer 
1 M Tris /HCl pH 8,45,  0,1%(w/v) SDS 
Cathode buffer 
100 mM Tris/HCl pH 8.25, 100 mM Tricin, 0,1%(w/v) SDS     
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